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ABSTRACT 
Worldwide, anxiety disorders are the sixth leading cause of all years of life lived with disability, 
ahead of diabetes, cancers and stroke. In the United States, anxiety disorders are the most 
common mental disorders among older adults. It is well documented that anxiety and cognitive 
impairment co-occur in older adults, however, the nature of this relationship remains unclear. 
Further, medications that are used to manage anxiety symptoms and disorders appear to be 
increasing in the general population with paucity of information about trends in older adults. 
Using three population-based studies, this dissertation investigated anxiety symptoms in older 
men and women with a focus on anxiety-related medications and impact of anxiety on future 
cognitive functioning. We found that the use of anxiolytic and antidepressant medications 
increased in an aging cohort over ten years with higher prevalence in women than men. We also 
found that some predictors of anxiolytic and antidepressant medications use were common 
among both men and women, while some predictors were potentially gender-specific. In a cohort 
of oldest old women, we found that mild anxiety symptoms were associated with increased odds 
of incident dementia over five years. We also found that change in anxiety symptoms over time 
was associated with increased risk of dementia. We did not observe an association between 
anxiety symptoms and mild cognitive impairment. In a cohort of older men, we found that 
anxiety symptoms were associated with greater declines in both global cognitive function and 
executive function over three years. We also found that such a decline reached clinically 
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significant level in executive function but not in global cognitive function. Taken together, these 
findings are of major public health relevance as they highlight the significance of anxiety 
symptoms in older adults. Findings from this research will improve our understanding of the role 
of anxiety as a predictor of future cognitive impairment. It is critical to clarify whether anxiety 
can early identify those at higher risk or it is a potentially modifiable risk factor. Findings 
from this research will also inform future intervention research that targets older users of 
anxiety-related medications. 
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1.0  INTRODUCTION 
Anxiety disorders refer to mental disorders that are characterized by excessive anxiety and fear 
and their related disturbances. Anxiety is a mood state associated with anticipation of possible 
future threat, whereas fear is an emotional response to real or perceived present or imminent 
threat. Anxiety disorders are distinguished from normal worry and fear by being excessive or 
persistent. (American Psychiatric Association, 2013) 
According to the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), anxiety disorders include the following nine diagnostic entities: separation 
anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, panic 
attack, agoraphobia, generalized anxiety disorder, substance/medication-induced anxiety disorder 
and anxiety disorder due to another medical condition. These subtypes of anxiety disorders differ 
from one another in terms of objects or situations that induce anxiety, fear and associated 
thoughts or beliefs. (American Psychiatric Association, 2013) 
It is noteworthy that the DSM-5 classification of anxiety disorders no longer includes 
obsessive-compulsive disorder, posttraumatic stress disorder or acute stress disorder, which 
were all classified as anxiety disorders in DSM-IV. (American Psychiatric Association, 2000) 
Further, anxiety disorders are categorized under the neurotic, stress-related and somatoform 
disorders chapter of the tenth revision of the International Statistical Classification of Diseases 
and Related Health Problems (ICD-10). 
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1.1 MEASUREMENT OF ANXIETY 
In clinical settings, diagnosis of anxiety disorders is based on the self-report of symptoms by the 
patient and the determination of whether the symptoms are typical, excessive or persistent by 
the clinician, while considering the patient’s overall health status. (American Psychiatric 
Association, 2013) In epidemiologic studies, anxiety is assessed using symptom scales 
or diagnostic schedules. (Murphy, 2011) 
Symptom scales assess the presence or absence of interrelated anxiety symptoms and 
their frequency on a numeric rating scale. (Murphy, 2011) A sum score is produced and a cutoff 
is used to define cases and non-cases. (Murphy, 2011) Diagnostic schedules assess the presence 
or absence of distinct anxiety syndromes and produce categorical diagnoses. (Murphy, 2011) 
Assessments made by diagnostic schedules are more comprehensive and are usually comparable 
to clinical interviews; however, they take longer time and are more expensive as they are 
interviewer-administered, which incur additional training costs. (Murphy, 2011) Thus, 
most epidemiologic investigations utilize symptom scales. (Murphy, 2011) 
A recent systematic review identified 91 assessment measures of anxiety that were used 
in studies with adults aged 65 years and older; however, only 12 of them were identified as the 
most commonly used tools in the literature (have been used in at least 6 studies). (Therrien & 
Hunsley, 2012) 
These common tools include the following instruments specific to anxiety: State Trait 
Anxiety Inventory (STAI; 40-item self-report questionnaire) (Spielberger, 1983); Hospital 
Anxiety and Depression Scale (HADS; 14-item self-report questionnaire) (Zigmond & Snaith, 
1983); Hamilton Anxiety Rating Scale (HARS; 14-item clinician-administered rating scale) 
(Hamilton, 1959); Goldberg Anxiety and Depression Scale (GADS; 18-item self-report 
3 
questionnaire) (Goldberg, Bridges, Duncan-Jones, & Grayson, 1988); Beck Anxiety Inventory 
(BAI; 21-item self-report questionnaire) (Beck, Epstein, Brown, & Steer, 1988); Penn State 
Worry Questionnaire (PSWQ; 16-item self-report questionnaire) (Meyer, Miller, Metzger, & 
Borkovec, 1990); Worry Scale (WS; 35-item self-report questionnaire) (Wisocki, Handen, & 
Morse, 1986), and Geriatric Anxiety Inventory (GAI; 20-item self-report questionnaire) 
(Pachana et al., 2007) 
Other common tools but are not specific to anxiety include Geriatric Mental State 
Examination (GMSE; semi-structured clinical interview) (Copeland et al., 1976), General Health 
Questionnaire (GHQ; 60, 30, 28, 20 and 12 items self-report questionnaires) (Goldberg, 1978), 
Brief Symptom Inventory (BSI, 53-item self-report questionnaire) (Derogatis & Spencer, 1982), 
and Symptom Checklist 90-R (SCL-90-R; 90-item self-report questionnaire). (Derogatis, 1994) 
The large majority of these common measures of anxiety were created for use in younger 
adults and there is lack of psychometric evidence to support their use in older adults. (Therrien & 
Hunsley, 2012) Of the 12 common measures, 3 measures were developed specifically for older 
adults (GAI, GMSE, WS), and 3 measures had sufficient psychometric evidence to warrant their 
use in older adults (BAI, GMSE, PSWQ). (Therrien & Hunsley, 2012) More recently, the 
Geriatric Anxiety Scale (GAS; 30-item self-report questionnaire) was developed as a new 
measure of anxiety for use with older adults. (Segal, June, Payne, Coolidge, & Yochim, 2010) 
It is important to highlight that assessment of anxiety in older adults is complicated in 
several ways. First, strong co-morbidity of anxiety and depression may lead to misclassification 
if the assessment tool does not adequately differentiate between symptoms of both conditions. 
(Therrien & Hunsley, 2012) Second, increased frequency of medical conditions in older adults 
may lead to misclassification if the assessment tool includes high number of somatic symptoms 
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related to medical conditions that could be attributed by participants or interviewers to anxiety. 
(Therrien & Hunsley, 2012) Finally, cognitive status and medications use are important 
considerations when assessing anxiety in older adults as they may alter presentation and 
communication of anxiety symptoms. (Therrien & Hunsley, 2012) 
1.2 EPIDEMIOLOGY OF ANXIETY 
Globally, Baxter, Scott, Vos, and Whiteford (2013) conducted a systematic review and meta-
regression analyses that included 87 studies from 44 countries to estimate prevalence of anxiety 
disorders. Adjusted for methodological differences across studies, the authors estimated the 
global current prevalence of anxiety disorders as 7.3% and it ranged from 5.3% in African 
countries to 10.4% in countries in Western Europe, North America and Australasia. (Baxter et 
al., 2013) 
In the United States, recent estimates of mental disorders prevalence are based on 
findings from the National Comorbidity Survey Replication. The National Comorbidity Survey 
Replication is a nationally representative survey of 9282 non-institutionalized adults aged 18 
years and older that utilized DSM-IV criteria to assess mental disorders. (Kessler, Chiu, Demler, 
Merikangas, & Walters, 2005) According to the National Comorbidity Survey Replication, 
anxiety disorders are the most common mental disorders in the United States with a lifetime 
prevalence of 28.8% (Kessler, Berglund, et al., 2005) and 12-month prevalence of 18.1%. 
(Kessler, Chiu, et al., 2005) 
Further analyses from the National Comorbidity Survey Replication showed that anxiety 
disorders are also common among older adults. The lifetime prevalence of any anxiety disorder 
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was estimated as 16.6% among women and 9.6% among men aged 65 years and older. (Gum, 
King-Kallimanis, & Kohn, 2009) In participants aged 55 years and older, the overall 12-month 
prevalence of anxiety disorders was estimated as 11.6% with the following age-specific 
estimates: 16.6% for 55-64 years group; 8.9% for 65-74 years group; 6.0% for 75-84 years group 
and 8.1% for ≥ 85 years group. (Byers, Yaffe, Covinsky, Friedman, & Bruce, 2010) The study 
reported that 14.7% of older women and 7.6% of older men had at least one anxiety disorder in 
the past year and that there were no differences in prevalence by race or ethnicity. (Byers et al., 
2010) The National Epidemiologic Survey on Alcohol and Related Conditions, another 
nationally representative survey in the United States, reported comparable estimates of anxiety 
disorders prevalence in older adults. (Reynolds, Pietrzak, El-Gabalawy, Mackenzie, & Sareen, 
2015) 
It is important to note that other studies reported a wide variation in the prevalence 
estimates of anxiety in older adults. (Bryant, Jackson, & Ames, 2008) In community samples, 
prevalence of anxiety disorders ranged from 1.2% in a New York sample aged 65-90 years 
(Copeland et al., 1987) to 14% in a French sample aged 65 years and older (Ritchie et al., 2004), 
while prevalence of anxiety symptoms ranged from 15% in an American sample aged 70-79 
years (Mehta et al., 2003) to 52.3% in a German sample aged 70-103 years. (Schaub & Linden, 
2000) In clinical samples, prevalence of anxiety disorders ranged from 1% in an Australian 
sample aged 65 years and older from a general hospital (Ames & Tuckwell, 1994) to 24% in an 
American sample aged 50 years and older from a primary care setting (Tolin, Robison, 
Gaztambide, & Blank, 2005), while prevalence of anxiety symptoms ranged from 15% in an 
Australian sample aged 61-96 years from a geriatric hospital (Ames et al., 1994) to 56% in an 
Australian sample aged 65 years and older from a general hospital. (Ames & Tuckwell, 1994)  
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These discrepant findings are most likely due to methodological differences across 
studies in terms of source population, age group, measurement tool and definition of anxiety. 
Nevertheless, current literature indicates that anxiety and its disorder are indeed common in older 
adults. 
Evidence regarding the incidence rates of anxiety in older adults is scarce. Based on 
analyses from the National Epidemiologic Survey on Alcohol and Related Conditions, Chou, 
Mackenzie, Liang, and Sareen (2011) reported 3-year incidence rates for anxiety disorders 
among participants aged 60 years and older that ranged from 0.58% for social phobia to 1.63% 
for generalized anxiety disorder. The study showed that older women were twice as likely to 
develop generalized anxiety disorder compared to older men (odds ratio = 2.26). (Chou et al., 
2011) Similar gender difference in incidence rate was reported by a study based on a 
representative sample in the Netherlands. (Bijl et al., 2002) Among participants aged 55-64 
years, the incidence rate per 100 person-years of any anxiety disorders was 5.20 for women and 
1.36 for men. (Bijl et al., 2002) 
Few longitudinal studies examined risk factors for anxiety in older adults. de Beurs, 
Beekman, Deeg, Van Dyck, and van Tilburg (2000) examined risk factors for change in anxiety 
symptoms in 2,165 older adults aged 55-85 years from the Longitudinal Aging Study Amsterdam 
over 3 years. The authors reported the significant independent predictors of becoming anxious, 
with standardized coefficients from multiple logistic regression models, as follows: female 
gender (3.60), neuroticism (3.81) and distress (2.68). (de Beurs et al., 2000) Further analyses 
from the same study, after excluding those with existing anxiety or depression (N=1,810 
participants), showed the following significant predictors, along with the corresponding adjusted 
odds ratio: higher initial anxiety symptoms (1.4), female gender (5.1), less received emotional 
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support (2.1), poor self-rated health (2.1), neuroticism (2.2) and lower self-efficacy (2.1). 
Furthermore, illness of the partner, illness or death of a family member, having major conflict, or 
having been victimized by crime, were all significantly associated with increased risk of anxiety 
symptoms in multivariate models, however, authors did not report effect size. (de Beurs et al., 
2001)  
Forsell (2000) studied 894 older adults (mean age = 84.5 years, 77.3% women) in 
Sweden to explore predictors of anxiety symptoms. The author reported that developing anxiety 
symptoms at 3-year follow-up was significantly associated with history of depression or anxiety 
(adjusted odds ratio = 4.5) and having no regular visitors (adjusted odds ratio = 3.5). Schoevers, 
Deeg, van Tilburg, and Beekman (2005) studied 2,173 older adults aged 65-84 years (63.1% 
women) from the Amsterdam Study of the Elderly to examine predictors of generalized anxiety 
disorder over 3 years of follow-up and reported that only personal history of depression or 
anxiety was a statistically significant predictor (adjusted odds ratio = 2.58). To summarize, it 
appears from the available evidence that female gender and history of anxiety or depression were 
the most consistent risk factors for anxiety in older adults.  
1.3 PUBLIC HEALTH BURDEN OF ANXIETY 
According to the 2010 Global Burden of Disease study, anxiety disorders were the sixth leading 
cause of all years of life lived with disability (YLD) in both high-income and low- and middle-
income countries, ahead of diabetes, cancers and stroke. (Baxter, Vos, Scott, Ferrari, & 
Whiteford, 2014) The study showed that anxiety disorders accounted for 509 YLDs per 100,000 
women and 272 YLDs per 100,000 men worldwide. (Baxter et al., 2014) 
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In older adults, de Beurs et al. (1999) utilized cross-sectional data of 659 participants 
aged 55-85 years from the Longitudinal Aging Study Amsterdam and reported that anxiety 
disorders and symptoms were significantly associated with one or more days when activities 
were limited due to health problems (versus no days), with adjusted odds ratio of 1.6 (95% 
confidence interval 1.2, 2.3) for anxiety disorders and 3.2 (95% confidence interval 1.9, 5.3) for 
anxiety symptoms. Further, Brenes et al. (2005) studied 1,002 disabled older women (average 
age 78.3 years) from the Women’s Health and Aging Study and found that anxiety symptoms 
were significantly associated with risk of developing another functional disability over 3 years 
with the following adjusted hazard ratios: 1.41 (95% confidence interval 1.08, 1.84) for difficulty 
in activities of daily living and 1.56 (95% confidence interval 1.14, 2.14) for difficulty in light 
housework. 
In terms of mortality, additional analyses from the Longitudinal Aging Study Amsterdam 
sample showed that the mortality rates at 7.5-year follow-up for participants with an anxiety 
disorder were 105.6 and 38.7 per 1000 person-years for men and women, respectively. (van Hout 
et al., 2004) The adjusted hazard ratios for mortality for men and women with anxiety disorders 
in the study were 1.78 and 0.89, respectively, but only were statistically significant for men. (van 
Hout et al., 2004) Additionally, Brenes et al. (2007) examined this relationship in 3,015 older 
adults aged 70-79 years from the Health Aging and Body Composition study over 7 years. The 
authors reported that anxiety symptoms were significantly associated with risk of all-cause 
mortality in African Americans (adjusted hazard ratio = 2.28) but not in Whites. (Brenes et al., 
2007) In conclusion, anxiety in older adults is a significant disabling condition that may increase 
risk of death. 
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1.4 TREATMENT OF ANXIETY 
Anxiety disorders in older adults are treated with pharmacotherapy or psychotherapy or both 
combined, (Lenze & Wetherell, 2011) (Hendriks, 2014) The focus of this dissertation is 
pharmacotherapy. In this dissertation, the term “anxiolytic” broadly refers to medications that are 
used to manage anxiety symptoms or disorders. Benzodiazepines represent the main class and 
the most commonly prescribed class among anxiolytic medications. (Lenze & Wetherell, 2011) 
Several other classes of medications are used to treat anxiety disorders and symptoms including 
non-benzodiazepine sedative-hypnotics, antidepressants, buspirone, anticonvulsants, 
antipsychotics and antihistamines, but most of these medications need more evidence to support 
their use in older adults. (Janicak, Marder, & Pavuluri) Increasing evidence suggests that 
antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin 
norepinephrine reuptake inhibitors (SNRIs), may be equally effective in older adults as in 
younger adults, and are now recommended as the first line of treatment for anxiety disorders. 
(Lenze & Wetherell, 2011) (Hendriks, 2014) Studies in clinical settings of older adults with 
anxiety disorders have confirmed high rates of benzodiazepine and antidepressant use in this 
patient population. (Benitez et al., 2008) (Uchida et al., 2009) (Preville et al., 2011)  
In terms of pharmacodynamics, benzodiazepines enhance the effect of gamma-
aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter in the brain. (Janicak 
et al., 2010) Based on the catecholamine hypothesis, SSRIs and SNRIs operate to inhibit 
reuptake of serotonin and norepinephrine into the presynaptic cell, which effectively increase 
availability of these neurotransmitters to bind to the postsynaptic receptor and potentiate their 
activity in the brain. (Janicak et al., 2010) In terms of pharmacokinetics, benzodiazepines are 
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generally classified as short acting or long acting depending on their potency, duration of clinical 
activity, dependency risk, and withdrawal symptoms. (Janicak et al., 2010) SSRIs vary by their 
ability to inhibit their cytochrome P450 isoenzyme metabolic activity and their elimination half-
lives. (Janicak et al., 2010) It is noteworthy that some studies suggest that oral clearance of 
benzodiazepines may be higher in women than in men. (Greenblatt et al., 2000) This may lead 
women to consume benzodiazepines in high dose and frequency to achieve optimal effect. 
Older adults are more susceptible to adverse effects of psychotropic medications due to 
age-related physiological changes altering medication absorption, distribution, metabolism and 
excretion.(Janicak et al., 2010; Lindsey, 2009) Medical co-morbidity and polypharmacy in older 
adults also affect pharmacokinetic and pharmacodynamic properties of these 
medications.(Janicak et al., 2010; Lindsey, 2009) 
Benzodiazepines use in older adults has been associated with several adverse outcomes 
including cognitive decline (Paterniti, Dufouil, & Alperovitch, 2002), hip fracture (Wagner et al., 
2004), falls (Landi et al., 2005) and disability. (Gray et al., 2006) Comparable, yet debatable, 
findings have been observed with antidepressants use as well.(Coupland et al., 2011; Darowski, 
Chambers, & Chambers, 2009; Gebara et al., 2014)  Further, the updated American Geriatrics 
Society Beers Criteria designated a number of antidepressants along with benzodiazepines as 
potentially inappropriate medications for use in older adults. (American Geriatrics Society Beers 
Criteria Update Expert, 2012) 
Benzodiazepines and antidepressants are widely used medications in the United States. 
For instance, dispensed prescriptions for alprazolam, a benzodiazepine medication, have 
increased from 43.3 million in 2008 to 49.2 million in 2012. (IMSHealth, 2013) Similarly, 
dispensed prescriptions for citalopram and sertraline, SSRI medications, have increased from 
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22.6 and 33.7 million in 2008 to 38.9 and 39.2 million in 2012, respectively. (IMSHealth, 2013) 
Further, clinicians wrote 37.6 benzodiazepine prescriptions per 100-person in 2012. (Paulozzi, 
Mack, & Hockenberry, 2014) 
Few longitudinal studies have explored patterns of anxiolytic medication use specifically 
in community-dwelling older adults in the United States. Dealberto, Seeman, McAvay, and 
Berkman (1997) studied 2,812 older adults aged 65 years and older from 1982 to 1988 and 
reported that benzodiazepines were used by 6.25% of the total sample and their use remained 
stable over time (5.96% in 1985 to 6.06% in 1988). The authors reported that women were 
about twice as likely as men to use benzodiazepines (7.65% versus 3.78%, p <0.001). 
(Dealberto, Seeman, et al., 1997) D. Blazer, C. Hybels, E. Simonsick, and J. T. Hanlon (2000) 
studied 4,000 community dwelling older adults aged 65 years and older from 1986 to 1996. For 
benzodiazepines, 12% and 10.2% of participants were users in 1986 and 1996, respectively. 
(D. Blazer et al., 2000) For non-benzodiazepine sedative-hypnotics, 1.6% and 0.7% of 
participants were users in 1986 and 1996, respectively. (D. Blazer et al., 2000) The authors 
reported the statistically significant predictors of sedative, hypnotic, and antianxiety 
medication use at four visits as follows, with the corresponding adjusted odds ratio for each 
factor: depressive symptoms (2.13), medical outpatient visits (2.30), female gender (1.87), 
fair or poor perceived health (2.12), white race (4.70) and impaired physical function (1.64). 
(D. Blazer et al., 2000) Utilizing the same sample but focusing on antidepressants, Blazer et 
al. (2000) found that use of these medications increased from 3.8% in 1986-1987 to 
11.0% in 1996-1997 and that female gender is a highly significant correlate at baseline but 
not at follow-up. (D. G. Blazer, C. F. Hybels, E. M. Simonsick, & J. T. Hanlon, 2000)  
Stowell, Chang, Bilt, Stoehr, and Ganguli (2008) studied 1,342 older adults aged 65 years and 
older from 1991 to 2002 to examine factors associated with sustained benzodiazepine use at
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two consecutive waves. At baseline, 9.8 % of women and 5.5 % of men were benzodiazepines 
users. (Stowell et al., 2008) The authors reported the statistically significant predictors of 
sustained benzodiazepine use as follows, with the corresponding adjusted odds ratio for 
each factor: female gender (2.57), two or more non-benzodiazepine prescription medications 
(5.20) and ever smoked (3.01). (Stowell et al., 2008) Overall, it appears from the few studies 
that were conducted that female gender is the most consistent correlate of anxiolytic 
medication use in older adults. 
1.5 COMORBIDITIES OF ANXIETY 
Literature documented comorbidity of anxiety in older adults with psychiatric conditions (such 
as depression, substance use), medical conditions (such as cardiovascular disease, respiratory 
disease, vestibular problems) and cognitive impairment (such as cognitive decline, severe 
cognitive impairment). (Wolitzky-Taylor, Castriotta, Lenze, Stanley, & Craske, 2010) 
(Beaudreau & O'Hara, 2008) The focus of this dissertation is the relationship between anxiety 
and cognitive impairment in older adults, which will be discussed in the following sections.  
1.5.1 Anxiety and cognitive impairment 
The focus of this dissertation is the general symptoms of anxiety that are often associated with 
generalized anxiety disorder. Generalized anxiety disorder is characterized by excessive and 
persistent anxiety and worry that are hard to control, cause significant distress or impairment and 
occur on more days than not for at least six months about a number of activities or events. 
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(AmericanPsychiatricAssociation, 2013) Other features of generalized anxiety disorder include 
somatic symptoms (being easily fatigued, muscle tension, sleep disturbance), cognitive 
symptoms (difficulty concentrating or mind going blank) and affective symptoms (irritability, 
restlessness or feeling keyed up or on edge). (AmericanPsychiatricAssociation, 2013) 
There are multiple lines of evidence that suggest an association between anxiety and 
cognitive impairment in older adults. First, cross-sectional studies documented lower cognitive 
function in older adults with heightened anxiety. Beaudreau and O'Hara (2009) studied 102 
community-dwelling older adults (median age 71 years) and found that elevated anxiety 
symptoms (measured by the Beck Anxiety Inventory) were significantly associated with poorer 
inhibition (measured by the Stroop Color and Word Test) and slower processing speed/shifting 
attention (measured by the Symbol Digit Modality Test). The authors found that elevated anxiety 
was not associated with episodic memory, semantic memory or word fluency.(Beaudreau & 
O'Hara, 2009) In another study of 48 community-dwelling older adults (mean age 69 years, 73% 
women), Stillman, Rowe, Arndt, and Moser (2012) found that anxiety symptoms (measured by 
the Symptom Checklist-90-Revised) had significant inverse relationship with global cognitive 
function (measured by the Repeatable Battery for the Assessment of Neuropsychological Status) 
and its sub-measures of visuospatial ability as well as immediate and delayed memory. The 
authors reported that anxiety symptoms were not associated with sub-measures of attention or 
language.(Stillman et al., 2012) Similarly, Yochim, Mueller, and Segal (2013) studied 120 older 
adults (mean age 74.9 years, 62% women) and reported that anxiety symptoms (measured by the 
Anxiety Geriatric Anxiety Scale) were significantly associated with reduced performance of 
immediate verbal memory (measured by California Verbal Learning Test) and executive 
function (Delis–Kaplan Executive Function System), including categorization and task 
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switching. In this study, anxiety symptoms were not related to verbal fluency 
performance.(Yochim et al., 2013) 
In a larger sample from the Longitudinal Aging Study Amsterdam, Bierman, Comijs, 
Jonker, and Beekman (2005) studied 2,615 participants (mean age 70.2 years, 51.1% women) 
and reported that mild anxiety symptoms (measured by the Hospital Anxiety and Depression 
Scale) were associated with better cognitive functioning, whereas severe anxiety symptoms were 
negatively associated with cognitive performance. This curvilinear relationship reached the level 
of significance for global cognitive function (measured by the Mini-Mental State Exam) and for 
measures of processing speed (measured by the Coding Task) and episodic memory (measured 
by the Auditory Verbal Learning Test) but not for fluid intelligence (measured by Raven 
Progressive Matrices). (Bierman et al., 2005) In another population-based sample, Wetherell, 
Reynolds, Gatz, and Pedersen (2002) studied 704 older adults (mean age 63.7 years, 59.1% 
women) from the Swedish Adoption/Twin Study of Aging and found that higher state anxiety 
(measured by the State Trait Personality Inventory-Anxiety subscale) was associated with poorer 
performance on tests for vocabulary (measured by the Synonyms test), verbal reasoning 
(measured by the Analogies test), visuospatial ability (measured by the Koh’s Block Design) and 
visual memory (Names and Faces and Thurstone’s Picture Memory). The authors found no 
significant effects of state anxiety on attention, working memory, visual reasoning and verbal 
knowledge.(Wetherell et al., 2002) The authors also did not find a curvilinear relationship 
between state anxiety and cognitive function, but they did find significant interaction between 
state anxiety and gender on two tests (Card Rotations and Digit Span), in which men 
performed worse compared to women. (Wetherell et al., 2002) State anxiety refers to temporary 
emotions and is distinguished from trait anxiety, a personality construct. (Spielberger,  1983)
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In another study of state anxiety, Curiel et al. (2012) studied 267 older adults (mean age 
61.84 years, 62.9% women) and found that state anxiety (measured by the State Trait Anxiety 
Inventory) had an inverse relationship with delayed verbal memory (measured by the Wechsler 
Memory Scale and the Buschke Selective Reminding Test). Finally, Mantella et al. (2007) 
studied a sample of older adults with generalized anxiety disorder (N=19, mean age 70.2 years, 
57.9% women), major depressive disorder (N=68, mean age 71.2 years, 69.1% women) and 
healthy controls (N=40, mean age 69.9 years, 55% years). Compared to healthy controls, anxious 
participants performed worse on measures of task switching (measured by the Trail Making Test 
part B), and short-term and delayed memory (measured by the California Verbal Learning Test). 
(Mantella et al., 2007) 
It is important to note that other studies with conflicting findings do exist. For instance, 
Airaksinen, Larsson, and Forsell (2005) reported that anxiety disorders as a broad category 
exhibited impairments in episodic memory and executive functions, but generalized anxiety 
disorder specifically did not affect cognitive performance. Similarly,Biringer et al. (2005) and 
Potvin et al. (2013) reported that anxiety had no or positive effect on cognitive function, 
respectively. Given the cross-sectional design of these studies, it is not possible to determine 
causality and whether anxiety precedes lower cognitive function or it is a consequence. 
Second, cross-sectional studies documented elevated anxiety symptoms in older adults 
with clinically assessed cognitive impairment. Lyketsos et al. (2002) studied a sample of older 
adults with mild cognitive impairment (N=320, mean age 75 years, 60% women) and dementia 
(N=362, mean age 77 years, 63% women) from the Cardiovascular Health Study and compared 
them to healthy controls (N=653) from the Cache County Study. They found that 21.5% of 
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dementia participants and 9.9% of mild cognitive impairment participants reported anxiety 
symptoms (measured by the Neuropsychiatric Inventory) compared to 5.8% of healthy controls. 
(Lyketsos et al., 2002) The authors reported that the difference in anxiety symptoms between the 
mild cognitive impairment group and the cognitively normal group was marginally significant 
but they did not test for difference between the dementia group and the cognitively normal 
group. (Lyketsos et al., 2002) Lopez et al. (2003) studied 1155 patients (69.8% women) with 
probable Alzheimer’s disease and classified severity of their cognitive deficits using the Mini-
Mental State Exam as follows: mild (score of 20 or more), moderate (score between 19 and 10) 
and severe (score of 9 or less). The authors found that anxiety symptoms (defined according to 
DSM-IV or DSM-III criteria) were significantly more common among patients with severe 
deficits (68%) compared to those with mild deficits (60%) or moderate deficits (62%). (Lopez et 
al., 2003) 
Geda et al. (2008) studied participants with mild cognitive impairment (N=319, median 
age 82 years, 42.6% women) and cognitively intact participants (N=1590, median age 79 years, 
50.3% women) from the Mayo Clinic Study of Aging. They found that 14% of mild cognitive 
impairment participants reported anxiety symptoms (measured by the Neuropsychiatric 
Inventory Questionnaire) compared to 5% of healthy controls with an adjusted odds ratio of 3.00 
(95% confidence interval 2.01, 4.48). (Geda et al., 2008) Potvin, Hudon, Dion, Grenier, and 
Preville (2011) compared participants with cognitive impairment no dementia (N=234) and 
cognitively intact participants (N=2180) in terms of anxiety disorders (assessed following DSM-
IV criteria). In men, they found that cognitive impairment no dementia was associated with 
subclinical generalized anxiety disorder with an adjusted odds ratio of 4.93 (95% confidence 
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interval 1.84, 13.23). However, cognitive impairment no dementia was not related to any clinical 
or subclinical anxiety disorder in women. (Potvin, Hudon, et al., 2011) 
In addition, Andreescu et al. (2014) studied 1,982 older adults (mean age 77.59 years, 
61.26% women) with normal or mild cognitive impairment from the Monongahela-
Youghiogheny Healthy Aging Team study. Participants were classified according to three 
definitions of mild cognitive impairment to isolate cognitive and functional deficits, and 
classified anxiety according to three questions adapted from the Penn State Worry Questionnaire. 
(Andreescu et al., 2014) The authors found that chronic severe anxiety was significantly 
associated with mild cognitive impairment by all definitions (with adjusted odds ratios that 
ranged from 1.52 to 1.80); recent-onset anxiety was significantly associated with mild cognitive 
impairment by non-amnestic (adjusted odds ratio = 1.94, 95% confidence interval 1.21, 3.11), 
and International Working Group criteria (adjusted odds ratio = 2.11, 95% confidence interval 
1.31, 3.42), and chronic mild worry was not associated with any definition of mild cognitive 
impairment. (Andreescu et al., 2014) Finally, given the cross-sectional design of these studies, it 
is not possible to determine causality and whether anxiety is a symptom of cognitive impairment 
or it precedes it. 
Third, two longitudinal studies suggested that anxiety increased the risk of progression of 
mild cognitive impairment to severe cognitive impairment. Palmer et al. (2007) followed older 
adults (mean age 84 years, 84.9% women) with mild cognitive impairment (N=47) and normal 
cognition (N=185) for three years.  Compared with 6% of participants with normal cognition, 
they reported that 83% of participants with both mild cognitive impairment and anxiety 
symptoms (assessed by the Comprehensive Psychopathological Rating Scale) developed 
dementia due to Alzheimer’s disease (adjusted relative risk = 34.4, 95% confidence interval 13.9, 
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85.8) while 41% of participants with only mild cognitive impairment developed Alzheimer’s 
dementia (adjusted relative risk = 10.6, 95% confidence interval 4.2, 26.8). (Palmer et al., 2007) 
Gallagher et al. (2011) followed 161 patients with mild cognitive impairment (mean age 
73.7 years, 43% women) for 27 months and found that anxiety (measured by the Behavioral 
Pathology in Alzheimer’s Disease rating scale) was associated with earlier conversion to 
Alzheimer’s disease (adjusted hazard ratio = 1.85, 95% confidence interval 1.1, 3.1). However, it 
is important to note that these findings are not universal. Devier et al. (2009) reported that state 
anxiety did not predict conversion to Alzheimer’s disease and that trait anxiety actually predicted 
lower risk of conversion. 
Fourth, there is a strong comorbidity between anxiety and depression, which itself is a 
potential risk factor for cognitive impairment. (Ganguli, 2009) (Byers & Yaffe, 2011) Based on 
the National Comorbidity Survey Replication, Kessler et al. (2003) reported that 59.2% and 
57.5% of participants with lifetime and 12-month major depressive disorder, respectively, also 
met criteria for an anxiety disorder. Further analyses from the National Comorbidity Survey 
Replication revealed that generalized anxiety disorder is strongly correlated with major 
depressive disorder (r=0.62) and dysthymia (r=0.55). (Kessler, Chiu, et al., 2005) High level of 
comorbidity was also found in a sample of older adults (mean age = 70.96) in which 47.5% of 
those with depression also met criteria for anxiety, and 26.1% of those with anxiety also met 
criteria for depression. (Beekman et al., 2000) To summarize, there is a great overlap between 
anxiety and depression in older adults in terms of risk profile (Vink, Aartsen, & Schoevers, 
2008), presentation and treatment (Lenze, 2003), which may indicate some overlap in the 
underlying etiology that links these conditions with cognitive impairment. 
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Fifth, a number of studies reported that use of benzodiazepine, an anxiolytic medication, 
was associated with risk of cognitive decline or impairment. Four longitudinal studies reported 
an increased risk for cognitive decline or dementia (Lagnaoui et al. (2002); Paterniti et al. 
(2002); Gallacher et al. (2012); Billioti de Gage et al. (2012) (Billioti de Gage et al., 2014)), 
while other longitudinal studies reported no association (Hanlon et al. (1998); Allard, Artero, and 
Ritchie (2003)) or even lower risk for cognitive impairment (Dealberto, McAvay, Seeman, and 
Berkman (1997); Fastbom, Forsell, and Winblad (1998)). 
In all these studies, only two studies did account for anxiety (Paterniti et al., 2002) 
(Billioti de Gage et al., 2014), which raises the likelihood of confounding by indication in the 
reported findings. It is important to note that while the short-term effect of benzodiazepine use 
on cognition is established (Janicak et al.), the biological plausibility of its long-term effect on 
cognition is unknown. (Verdoux, Lagnaoui, & Begaud, 2005) Therefore, it is possible that 
benzodiazepine use could be a marker of an underlying condition, such as anxiety, that led to the 
reported association with cognitive impairment in several studies. 
Sixth, neuroticism, a personality trait characterized by a tendency to respond with 
negative emotions to stress (Lahey, 2009) and is closely related to anxiety, have been shown by 
one research group to be associated with cognitive decline (Wilson et al., 2005), mild cognitive 
impairment Wilson et al. (2007) and Alzheimer’s disease. (Wilson et al., 2006) More recently, 
they found that the anxiety facet of neuroticism was associated with increased risk of 
Alzheimer's disease and more rapid decline in global cognition in 785 older adults (mean age 
80.7 years) over 3.4 years. (Wilson, Begeny, Boyle, Schneider, & Bennett, 2011) However, 
Wetherell et al. (2002) found no support for neuroticism as a predictor of cognitive decline over 
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time in cognitively intact 704 older adults (mean age 63.7 years, 59.1% women) from the 
Swedish Adoption/Twin Study of Aging. 
Seventh, there are potential biological mechanisms that may explain the relationship 
between anxiety disorders and cognitive impairment. The most prominent biological pathway is 
based on the glucocorticoid-cascade hypothesis of stress and aging. (Sapolsky, Krey, & 
McEwen, 1986) This pathway postulates that high levels of glucocorticoid hormones result in 
structural and functional damage to the hippocampus and prefrontal cortex, most notably 
atrophy, which eventually result in cognitive impairment. (McEwen, 2012) The high levels of 
glucocorticoid hormones indicate dysfunction in hypothalamic-pituitary-adrenal (HPA) axis, a 
neuroendocrine mediator of stress. (McEwen, 2012) In response to stress, HPA axis operates in a 
series of feedback loops starting with the hypothalamus producing corticotropin-releasing 
hormone (CRH) that stimulates the pituitary gland to secrete adrenocorticotropic hormone 
(ACTH). Next, ACTH stimulates the adrenal cortex to produce glucocorticoid hormones, mainly 
cortisol. High cortisol levels regulate CRH and ACTH production via negative feedback. 
Chronic anxiety may cause HPA axis hyperactivity, which initiates this cascade. (McEwen, 
2012) The next potential biological pathway is based on the vascular depression hypothesis, 
which posits that cerebrovascular disease may predispose, precipitate, or perpetuate depressive 
symptoms, and subsequently result in cognitive impairment. (Alexopoulos et al., 1997) Given the 
strong comorbidity between both anxiety and depression, this same pathway may pertain to 
anxiety as well. Further, some studies found association between anxiety, and cardiovascular 
disease and diabetes, which provide additional support to this hypothesis in anxiety. (Wolitzky-
Taylor et al., 2010) Another potential biological pathway is that individuals with anxiety may 
have genetic polymorphisms that increase their vulnerability to cognitive impairment at older 
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age. For instance, short (S) allele of the serotonin transporter-linked polymorphic region (5-
HTTLPR), responsible for a reduced level of serotonin in the brain, has been linked to anxiety 
disorders (Stein, Schork, & Gelernter, 2008) and dementia. (Bertram, McQueen, Mullin, 
Blacker, & Tanzi, 2007) Finally, cellular aging in individuals with anxiety may increase their 
risk of cognitive impairment at older age. Telomere is a DNA sequence that caps chromosomes 
and is shortened in subsequent cell divisions. (Sanders & Newman, 2013) Though inconclusive, 
emerging evidence suggests that a shorter leukocyte telomere length is associated with cognitive 
function. (Sanders & Newman, 2013) More recently, Shalev et al. (2014) reported that 
internalizing disorders, such as generalized anxiety disorder, were associated with shorter 
leukocyte telomere length cross-sectionally and longitudinally over 12 years. In conclusion, there 
are several biological mechanisms that may potentially explain, jointly or independently, the 
relationship between anxiety and cognitive impairment; however, more research is needed to 
better understand these mechanisms. 
The above-mentioned multiple lines of evidence are complex and may be interpreted in 
different ways. First, anxiety could be a consequence of cognitive impairment, as a prodromal 
symptom of undiagnosed condition causing cognitive impairment, or as a psychological reaction 
to early cognitive deficits. This prodromal hypothesis can be ruled out by utilizing longitudinal 
studies in which anxiety is assessed at baseline in a cognitively intact sample. Next, association 
between anxiety and cognitive impairment could be confounded by shared risk factors, such as 
depression. This interpretation can be ruled out via statistical adjustment for potential 
confounding factors, with the assumption that the measured variable is valid, or possibly by 
excluding participants with these factors. 
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Finally, anxiety could be a cause or risk factor for cognitive impairment. Anxiety may be 
implicated in the causal pathway leading to cognitive impairment, directly via patho-
physiological mechanisms, or indirectly via behavioral risk factors that drive patho-physiological 
mechanisms. The etiological hypothesis can be confirmed by utilizing longitudinal studies in 
which bias and confounding are minimized and potential biological and behavioral mediators can 
be tested. To conclude, longitudinal research is critical in interpreting the above-mentioned 
multiple lines of evidence and in understanding the complex relationship between anxiety and 
cognitive impairment in older adults. 
1.5.2 Longitudinal research on anxiety and cognitive impairment 
In total, 12 longitudinal studies investigated whether anxiety in cognitively normal older adults 
predicted incident cognitive impairment or decline. (Appendix A) 
 In terms of study design, two studies had a case-control design (Burton, Campbell, 
Jordan, Strauss, and Mallen (2013) (Zilkens, Bruce, Duke, Spilsbury, & Semmens, 2014), while 
all the other studies had a prospective cohort design. All the studies were conducted in high-
income countries with four studies conducted in Australia, two studies conducted in each of the 
Netherlands, the United Kingdom and the United States, and one study conducted in each of 
Canada and Israel. Sample size in the studies ranged from 137 in the study by Sinoff and Werner 
(2003) to 16,351 in the study by Okereke and Grodstein (2013), but the majority of the studies 
had sample sizes exceeding one thousand participants. 
 All studies comprised community-dwelling older adults except for three studies as 
follows: Sinoff and Werner (2003) studied individuals who were referred to a geriatric 
assessment unit, Burton et al. (2013) studied patients registered in 10 primary care practices, and 
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Zilkens et al. (2014) utilized administrative health records. All samples included men and 
women except for the study by Gallacher et al. (2009) that included only men and the study by 
Okereke and Grodstein (2013) that included only women. The average age in the studies was in 
the sixties and seventies except for two studies as follows: Burton et al. (2013) studied cases and 
controls with a mean age of 81.40 and 80.87 years, respectively and Gallacher et al. (2009) 
studied men with a mean age of 56.1 years. The follow-up duration in the prospective cohort 
studies ranged from 1 to 17 years with about half of the studies with a follow-up duration of 4 
years or less. In two studies, participants with more anxiety symptoms and lower cognitive 
performance had higher dropout rates from the study. (Bierman, Comijs, Rijmen, Jonker, & 
Beekman, 2008)  Gallacher et al. (2009) 
 The large majority of the studies assessed anxiety symptoms and two of the studies 
assessed anxiety disorders in addition to symptoms. (Potvin, Forget, Grenier, Preville, & Hudon, 
2011) (de Bruijn et al. (2014) One study assessed pathologic worry specifically (Pietrzak et al., 
2012), one study assessed phobic anxiety symptoms specifically (Okereke and Grodstein, 2013), 
and one study utilized informant-report measure to assess anxiety. (Geda et al., 2014) With the 
exception of one study (Bierman et al., 2008), anxiety was analyzed as a categorical exposure 
variable indicating the presence or absence of anxiety symptoms or disorders in all studies. 
 To assess cognitive impairment, six studies utilized cognitive function tests and six 
studies utilized clinical adjudication. Two of the studies that used cognitive testing had a cutoff 
to define a dichotomous variable for cognitive impairment (Sinoff and Werner (2003) (Potvin, 
Forget, et al., 2011), while the other four predicted decline in cognitive function as a continuous 
variable. Bierman et al. (2008) Pietrzak et al. (2012) (Okereke and Grodstein, 2013) (Pietrzak et 
al., 2015) The studies that utilized clinical adjudication either assessed mild (Cherbuin et al., 
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2009) (Geda et al., 2014) or severe (Burton, Campbell, Jordan, Strauss, and Mallen (2013) de 
Bruijn et al. (2014) cognitive impairment, with only one study that assessed both levels of 
cognitive impairment. Gallacher et al. (2009) de Bruijn et al. (2014) also assessed cognitive 
decline. However, none of the studies comprehensively assessed decline in specific cognitive 
tests and both levels of clinically assessed cognitive impairment (mild cognitive impairment and 
dementia). 
 Two studies did not adjust for depression (Gallacher et al. (2009) (Geda et al., 2014) and 
three of the studies did not account for cardiovascular diseases or other chronic medical 
conditions. (Sinoff and Werner (2003) Pietrzak et al. (2012) de Bruijn et al. (2014) Only three 
studies adjusted for psychotropic medication use. Bierman, Comijs, Rijmen, Jonker, and 
Beekman (2008) Cherbuin et al. (2009)  (Potvin, Forget, et al., 2011) All these factors are known 
to be associated with anxiety and cognitive impairment and thus are potential confounding 
factors that need to be taken into account. (Wolitzky-Taylor et al., 2010) (Beaudreau & O'Hara, 
2008) 
 In total, eight studies reported that anxiety significantly predicted increased cognitive 
impairment or decline while four studies found no association. In the studies that reported 
positive association between anxiety and cognitive impairment or decline, the effect size ranged 
from an adjusted hazard ratio of 1.87 reported by Geda et al. (2014) to an adjusted odds ratio of 
6.27 reported by Potvin, Forget, et al. (2011). Two of the studies reported gender differences in 
which anxiety had smaller effect (Potvin, Forget, et al., 2011) or no effect (Burton et al., 2013) in 
women compared to men. 
 Several methodological limitations may explain the contradictory findings reported by 
the longitudinal studies that investigated the association between anxiety and subsequent 
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cognitive impairment in older adults. The studies utilized diverse samples with different age 
structure. It is possible that the risk profile for cognitive impairment within the source 
populations in these studies is not similar. It is also likely that the association between anxiety 
and cognitive impairment varies by the age group. 
 In terms of exposure assessment, there was a wide variation across studies regarding 
anxiety measurement tools and definitions. Anxiety in most of these studies was not assessed 
clinically. Relying on self-report or informant-report symptom scales or medical records rather 
than objective assessments may have led to misclassification. Outcome definitions were 
heterogeneous as well and many studies relied on cognitive function tests without clinical 
judgment. This also may have led to misclassification. 
 Furthermore, studies varied considerably in their consideration of potential confounding 
factors such as depression, psychotropic medications and chronic medical conditions. This may 
have distorted the reported findings and made it difficult to disentangle the effect of anxiety. In 
addition, losses to follow-up in two studies were associated with anxiety and cognitive 
impairment, which may have biased the results. About half of the studies had follow-up duration 
of four years or less. Cognitive impairment is a degenerative condition with a long prodromal 
period during which prodromal anxiety symptoms may appear before a formal diagnosis is 
established. Therefore, it is important to have long follow-up duration to ensure that participants 
at the baseline are truly cognitively intact. In summary, more studies addressing these limitations 
are needed in order to clearly understand the relationship between anxiety and subsequent 
cognitive impairment in older adults. 
 The literature that examined the longitudinal relationship between anxiety and cognitive 
impairment in older adults has a number of gaps. First, only two studies, one based on informant-
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reported anxiety and one based on phobic anxiety, were conducted in the United States and this 
limits the generalizability of findings to this country. Second, no prospective cohort studies were 
conducted in the oldest old (80 years and older) population that may have different 
characteristics leading to their survival to this old age. Therefore it is important to examine how 
anxiety predicts future cognitive functioning in this unique population. 
 Third, there were no prospective cohort studies that investigated how characteristics of 
anxiety are related to cognitive impairment. Variables such as number of anxiety symptoms, 
specific symptoms of anxiety and change in anxiety over time are important unexplored 
characteristics that may shed light on the complex relationship between anxiety and cognitive 
impairment. Fourth, none of the studies examined the effect of anxiety across the full cognitive 
spectrum, which spans cognitive decline, mild cognitive impairment and severe cognitive 
impairment. This is particularly important to identify possible trends in the relationship between 
anxiety and cognitive impairment and to facilitate comparison of findings across studies. Fifth, 
many previous studies did not account for critical potential confounding factors such as 
depression, psychotropic medications and chronic medical conditions. 
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2.0  SPECIFIC AIMS 
2.1 ANXIOLYTIC MEDICATIONS USE IN OLDER ADULTS 
In the general population, use of medications that are used to manage anxiety symptoms and 
disorders appears to be increasing. However, it remains unknown whether these recent trends are 
similar in older adults.  Most of the longitudinal community-based studies that examined 
anxiolytic medications in older adults were conducted in the 1980s and 1990s. Given the serious 
adverse effects of these medications in older adults, it is important to examine trends of their use 
in more recent years and to understand the profile of their users in the community. Further, 
literature showed that female gender is the most consistent correlate for anxiolytic medications 
use with higher prevalence among women than men.  Gender-specific predictors of use of these 
medications remain unclear and understudied. Since women have greater life expectancy and 
represent a larger proportion of older adults, it is crucial to understand the socio-demographic 
and health-related predictors of their use of anxiolytic medications. Understanding patterns and 
correlates of anxiolytic medications use over time will inform future programs that aim to reduce 
inappropriate use of medications in older adults.  
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2.1.1 Specific Aim 1 
We aim to investigate the trend of anxiolytic and antidepressant medications use, and to 
investigate gender-specific predictors of use of these medications over time among older 
community-dwelling men and women in the Health, Aging and Body Composition Study. 
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2.2 ANXIETY AND COGNITIVE IMPAIRMENT IN OLDER ADULTS 
The longitudinal relationship between anxiety symptoms and subsequent cognitive impairment in 
older adults remains unclear. Previous research examining this relationship has reported 
contradictory findings, and was limited by small sample size, short follow-up, not accounting for 
important confounders and measurement issues. Previous longitudinal studies also did not 
investigate the role of specific characteristics of anxiety symptoms in relation to cognitive 
impairment. Further, it is important to explore the relationship between anxiety symptoms and 
cognitive impairment separately for each gender. Female gender is the most consistent correlate 
and risk factor for anxiety symptoms and disorders. Women with anxiety have higher disability 
compared to men and men with anxiety have higher mortality compared to women. These 
findings may reflect unique pathophysiological profiles in men and women due to biological, 
environmental or cultural differences. Finally, it is important to disentangle the independent 
influence of anxiety on cognitive impairment from depression, given their strong comorbidity. 
Addressing present gaps in literature will help in understanding the role of anxiety as a predictor 
of future cognitive impairment and whether anxiety is a potentially modifiable risk factor or can 
early identify those at higher risk. Findings will direct future studies that aim to explore potential 
mechanisms underlying both conditions that are specific to older men or older women. 
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2.2.1 Specific Aim 2 
We aim to investigate the relationship between presence, level and changes of anxiety 
symptoms, and risk of future dementia, MCI and decline in cognitive functioning among the 
oldest old community-dwelling women in the Study of Osteoporotic Fractures. 
2.2.2 Specific Aim 3 
We aim to investigate the relationship between presence and level of anxiety symptoms, and risk 
of future cognitive decline among older community-dwelling men in the Osteoporotic Fractures 
in Men Study. 
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3.0  PAPER 1: TRENDS AND GENDER-SPECIFIC PREDICTORS OF ANXIOLYTIC 
AND ANTIDEPRESSANT MEDICATIONS USE IN OLDER ADULTS 
3.1 ABSTRACT 
Background: Recent research investigating use of anxiolytic or antidepressant medications in 
older adults is limited. We examined the prevalence and trend of anxiolytic and antidepressant 
medications use in older adults and explored gender-specific predictors of their use over time. 
Methods: We studied 3,055 older community-dwelling adults (mean age = 73.63, SD ±2.87 
years) who were followed on average for 10.29 years. Medications were collected at 3 clinic 
visits and coded using the Iowa Drug Information Service scheme. We assessed a series of 
demographic, health status, life style and healthcare covariates. We used logistic regression 
models with generalized estimating equations to identify gender-specific predictors of anxiolytic 
and antidepressant medications use over time. Results: At baseline, 202 (6.61%) women used 
anxiolytic or antidepressant medications compared to 110 (3.60%) men. Use of these 
medications increased from 10.21% in 1997-1998 to 16.82% in 2007-2008. Caucasian race was 
an independent predictor of both anxiolytic and antidepressant medications use in both men and 
women. In men, independent predictors of medications use included 3 or more co-morbid 
medical conditions, getting influenza vaccine and poor/fair self-rated health. In women, 
independent predictors of medications use included a family income of $25,000 or less, anxiety 
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and depression. Conclusion: Our findings suggest that use of anxiolytic and antidepressant 
medications increased in this aging cohort and may have gender-specific predictors. Future 
studies should focus on prescribers to clarify whether the increasing trend in these medications is 
clinically indicated or reflects inappropriate use. 
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3.2 INTRODUCTION 
Anxiety disorders are the most prevalent mental health problems.(Kessler, Berglund, et al., 2005) 
Both anxiolytic and antidepressant medications are used to pharmacologically manage anxiety 
disorders.(Koen & Stein, 2011) In the United States, use of anxiolytic and antidepressant 
medications appears to be increasing in the general population.(Mojtabai & Olfson, 2014; 
Olfson, King, & Schoenbaum, 2015) For instance, dispensed prescriptions for alprazolam, an 
anxiolytic medication, have increased from 43.3 million in 2008 to 49.2 million in 
2012.(IMSHealth, 2013) Similarly, dispensed prescriptions for citalopram and sertraline, 
antidepressant medications, have increased from 22.6 and 33.7 million in 2008 to 38.9 and 39.2 
million in 2012, respectively.(IMSHealth, 2013) However, it remains unknown whether these 
recent trends are similar in older members of the general population. Most of the longitudinal 
community-based studies that examined anxiolytic or antidepressant medications use in older 
adults were conducted in the 1980s and 1990s.(D. G. Blazer et al., 2000; D. Blazer et al., 2000; 
Dealberto, Seeman, et al., 1997; Stowell et al., 2008) 
Older adults are more susceptible to adverse effects of psychotropic medications due to 
age-related physiological changes altering medication absorption, distribution, metabolism and 
excretion.(Janicak et al., 2010; Lindsey, 2009) Medical co-morbidity and polypharmacy in older 
adults also affect pharmacokinetic and pharmacodynamic properties of these 
medications.(Janicak et al., 2010; Lindsey, 2009) Use of benzodiazepine, a major anxiolytic 
class, in older adults has been associated with serious adverse outcomes including cognitive 
decline, hip fracture, falls and disability.(Gray et al., 2006; Landi et al., 2005; Paterniti et al., 
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2002; Wagner et al., 2004) Comparable, yet debatable, findings have been observed with 
antidepressants use as well.(Coupland et al., 2011; Darowski et al., 2009; Gebara et al., 2014) 
The updated American Geriatrics Society Beers Criteria designated several antidepressants along 
with benzodiazepines as potentially inappropriate medications for use in older adults due to their 
unfavorable risk-benefit ratio.(American Geriatrics Society Beers Criteria Update Expert, 2012) 
Due to increased vulnerability and potential for inappropriate use, it is important to 
examine trends of anxiolytic and antidepressant medications use by older adults in more recent 
years. To inform possible interventions, it is also important to understand the profile of 
anxiolytic and antidepressant medications users in the community and to explore such profile 
separately for men and women. Literature shows that gender is the most consistent correlate of 
anxiolytic and antidepressant medications use, with higher prevalence among women than 
men(D. G. Blazer et al., 2000; D. Blazer et al., 2000; Dealberto, Seeman, et al., 1997; Stowell et 
al., 2008). While reasons for such disparity remain unclear and understudied(Voyer, Cohen, 
Lauzon, & Collin, 2004), it may reflect unique characteristics of men and women due to 
biological, environmental or cultural differences. 
In this longitudinal study, we assessed the prevalence and trend of anxiolytic and 
antidepressant medications use in older community-dwelling adults over ten years and examined 
predictors of anxiolytic and antidepressant medications use in both men and women over time. 
We hypothesized that older adults will exhibit increasing use of anxiolytics and antidepressants 
over time and that men and women will have different predictors of their anxiolytics and 
antidepressants use. 
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3.3 METHODS 
3.3.1 Population 
We utilized data from the Health, Aging, and Body Composition (Health ABC) study, a 
prospective cohort study of community-dwelling older adults aged 70 to 79 years.(Newman et 
al., 2003) In brief, 3,075 African-American and Caucasian men and women were recruited 
during 1997-1998 from Pittsburgh, Pennsylvania and Memphis, Tennessee using Medicare 
beneficiary lists. Subjects were not enrolled in Health ABC if they had difficulty carrying out 
basic activities of daily living, walking quarter of a mile, or climbing ten steps without resting. 
The institutional review board at each site approved the study and participants provided written 
informed consent. 
For this analysis, we used data collected at baseline (1997-1998), year 6 (2002-2003), and 
year 11 (2007-2008). Our analytical sample included 3,055 participants as 20 participants had 
incomplete medication use information at baseline. 
3.3.2 Measurement of medication use 
At clinic visits, participants were asked to bring all prescription and over-the-counter 
medications they had taken in the past two weeks. Medications were coded and categorized 
using the Iowa Drug Information Service (IDIS) scheme.(Pahor et al., 1994) At year 11, non-
prescription medications were no longer collected and the period of time during which 
the medication was last used was changed from two weeks to 30 days. The dependent variables 
were use versus no use of anxiolytic and antidepressant medications at baseline, year 6 and year 
11.
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Anxiolytic medications included the following classes with their respective 
medications(Hendriks, 2014; Lenze & Wetherell, 2011): benzodiazepine anxiolytics 
[BZDs] (alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, lorazepam and 
oxazepam); and non-benzodiazepine anxiolytics [NBZDs] (buspirone, butabarbital, 
hydroxyzine, meprobamate and pregabalin). Antidepressant medications included the 
following classes with their respective medications: selective serotonin norepinephrine 
reuptake inhibitors [SNRIs] (desvenlafaxine, duloxetine, milnacipran and venlafaxine); selective 
serotonin reuptake inhibitors [SSRIs] (citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine and sertraline); and tricyclic antidepressants [TCAs] (amitriptyline, amoxapine, 
clomipramine, desipramine, doxepin, imipramine, nortriptyline and trimipramine).  
3.3.3 Measurement of covariates 
Participant baseline characteristics included the following categories: socio-demographic, health-
related, life style and healthcare. Socio-demographic factors included gender, age, race (African-
American versus Caucasian), education (less than high school versus high school or higher), 
marital status (married versus widowed, divorced, separated or never married), annual family 
income ($25,000 or less versus more than $25,000), and study site.  
Health-related factors included self-rated health status (poor or fair versus good, very 
good or excellent), functional limitation due to hearing problems, functional limitation due to 
vision problems and body mass index (BMI). Self-reports of physician’s diagnoses of select 
medical conditions were summed to create a co-morbidity index (three or more versus two or 
less). Medical conditions included stroke, Parkinson's disease, myocardial infarction, congestive 
heart failure, chronic obstructive pulmonary disease, diabetes, hypertension, arthritis and cancer. 
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Bodily pain in the past 30 days (any versus none) was assessed. Functional status was assessed 
by collecting information on limitation (any versus none) with five instrumental activities of 
daily living (IADL), which included walking two to three blocks on level ground, climbing up to 
ten steps, preparing meals, doing heavy housework, and shopping for groceries. 
Poor sleep was defined as frequently not getting enough sleep or feeling sleepy during the 
day.(Mehta et al., 2003) Anxiety was defined as a positive response (Yes) to at least two of the 
three items from the anxiety subscale of the Hopkins Symptom Checklist.(Wright et al., 2009) 
The three items were: 1) During the past week, have you felt nervous or shaky inside; 2) During 
the past week, have you felt tense or keyed up; and 3) During the past week, have you felt 
fearful. Depression was defined as a score of 16 or more on the Center for Epidemiologic Studies 
- Depression (CES-D) scale.(Radloff, 1977) Cognitive function was assessed using Teng’s 
Modified Mini-Mental State (3MS) exam (score 0-100).(Teng & Chui, 1987)  
Life style factors included smoking (current, former, never) and alcohol use (current, 
former, never). Healthcare factors included having a primary care provider, having supplemental 
health insurance for prescription medications and getting influenza vaccine in the past year. 
3.3.4 Statistical analysis 
We calculated descriptive statistics for all variables and compared baseline characteristics of 
users and non-users of anxiolytic and antidepressant medications stratified by gender. For these 
comparisons, we used chi-squared test for categorical variables (or Fisher's exact test for low 
expected cell counts), the two-sample t-test for normally distributed continuous variables and the 
Wilcoxon rank-sum test for skewed continuous variables. Next, we calculated the frequency of 
anxiolytic and antidepressant medications use for each interview wave stratified by gender and 
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we tested for trend of medication use over time using Wald tests. Finally, we examined the 
predictors of anxiolytic and antidepressant medications use over time using logistic regression 
models with generalized estimating equations (GEE) to account for within-subject correlations. 
We used unstructured correlation structure and we modeled Time as continuous variable 
indicating years from baseline.  We fit the models in the full sample and we included product 
terms of gender by each variable to test for interaction. We additionally fit the models for men 
and women separately. Marital status, self-rated health, anxiety, depression, 3MS score, smoking 
and alcohol use were entered as time-varying variables. We assessed each variable in univariable 
models and then we fit multivariable model in which all variables were entered together and the 
model was progressively reduced until all predictors were significant at p <0.05. Clinic site was 
enforced in all the multivariable models. All statistical analyses were conducted with Stata 
version 13.1 (StataCorp LP, College Station, TX, USA). 
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3.4 RESULTS 
Participants were followed on average for 10.29 years (standard deviation [SD] ±0.12). By year 
6, a total of 377 participants died, 75 participants were lost to follow-up and 88 participants did 
not have medication use data, leaving 2,515 participants with complete data for this interview 
wave. By year 11, a total of 557 participants died, 114 lost to follow-up and 507 did not have 
medication use data, leaving 1,337 participants with complete data for this interview wave.  
3.4.1 Characteristics of participants 
Baseline characteristics of users and non-users of anxiolytic medications stratified by gender are 
presented in Table 3.6.1. Among men, users of anxiolytic medications were more likely to be 
Caucasian, married, have poor or fair self-rated health, three or more co-morbid medical 
conditions, IADL limitations, anxiety and having primary care providers. Among women, users 
of anxiolytic medications were more likely to have family income of $25,000 or less, limitations 
due to hearing problems, IADL limitations, bodily pain, poor sleep, anxiety and depression. 
Baseline characteristics of users and non-users of antidepressant medications stratified by 
gender are presented in Table 3.6.2. Among men, users of antidepressant medications were more 
likely to have poor or fair self-rated health, IADL limitations, anxiety and have received 
influenza vaccine in the past year. Among women, users of anxiolytic antidepressant were more 
likely to be Caucasian, have completed high school or higher education, have limitations due to 
hearing problems, IADL limitations, poor sleep, anxiety and depression. 
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3.4.2 Trends of anxiolytic and antidepressant medications use 
Table 3.6.3 presents the proportion of anxiolytic and antidepressant medications users by gender 
for each interview wave. At baseline, 202 (6.61%) women used anxiolytic or antidepressant 
medications compared to 110 (3.60%) men. This gap in use between men and women remained 
at year 6 and year 11 with higher prevalence of medication use in women than in men. This 
pattern was also consistent across classes of medications except for SNRIs, which were used by 
more men than women at baseline and at year 6. Table 2 also shows a statistically significant 
increasing trend in use of medications in both men and women. This increasing trend was 
apparent in use of BZDs, SNRIs and SSRIs in both men and women. There was a decreasing 
trend of TCAs use in men only. There was no consistent trend in use of NBZDs among either 
men or women. 
3.4.3 Predictors of anxiolytic and antidepressant medications use in the full sample 
Findings from the GEE logistic regression models for anxiolytics and antidepressants are 
presented in Table 3.6.4. In unadjusted models, significant predictors of anxiolytic medications 
use over time were female gender, Caucasian race, poor/fair self-rated health, greater medical co-
morbidity, IADL limitations, bodily pain, anxiety and having a primary care provider. In the 
multivariable model, race, family income, medical co-morbidity, IADL limitations, anxiety and 
having a primary care provider were significant independent predictors of anxiolytics use. For 
antidepressants, significant predictors over time were female gender, Caucasian race, poor/fair 
self-rated health, 3 or more co-morbid medical conditions, IADL limitations, bodily pain, poor 
sleep, anxiety, depression, having a primary care provider and taking influenza vaccine in the 
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past year. In the multivariable model, gender, race, IADL limitations, anxiety and depression 
remained significant independent predictors of antidepressants use. In the models for anxiolytics, 
only the interaction term of gender by marital status was statistically significant (p=0.01). In the 
models for antidepressants, only the interaction terms of gender by limitation due to hearing 
problems, smoking status and BMI were marginally significant (p<0.10). 
3.4.4 Predictors of anxiolytic medications use by gender 
Findings from the GEE logistic regression models for BZDs and NBZDs are presented in Table 
3.6.5. In unadjusted models, among men, significant predictors of anxiolytic medications use 
over time were Caucasian race, being married, poor/fair self-rated health, greater medical co-
morbidity, IADL limitations, anxiety and smoking status (Wald (2) = 6.52, p-value = 0.04). In 
the multivariable model, only race, self-rated health, medical co-morbidity and anxiety remained 
significant independent predictors. In women, significant predictors of anxiolytic medications 
use over time were Caucasian race, poor/fair self-rated health, IADL limitations, bodily pain, 
anxiety and depression. In the multivariable model, Caucasian race, low family income and 
anxiety were significant independent predictors. 
3.4.5 Predictors of antidepressant medications use by gender 
Findings from the GEE logistic regression models for SNRIs, SSRIs and TCAs are presented in 
Table 3.6.6. In men, significant predictors of antidepressant medications use over time were 
Caucasian race, having high family income, poor/fair self-rated health, anxiety, depression, a 
primary care provider and receiving influenza vaccine. In the multivariable model, race, self-
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rated health, IADL limitations and influenza vaccine were significant independent predictors. In 
women, significant predictors of antidepressant medications use over time were Caucasian race, 
having limitation due to hearing problems, IADL limitations, bodily pain, poor sleep, anxiety, 
depression, and receiving influenza vaccine. Only race, IADL limitations, anxiety and depression 
remained significant predictors in the multivariable model for women.  
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3.5 DISCUSSION 
This longitudinal study showed that the use of anxiolytic and antidepressant medications in 
community-dwelling older adults increased from 10.21% in 1997-1998 to 16.82% in 2007-2008, 
with higher levels in women than men. For both classes of medications, Caucasian race, any 
IADL limitations and anxiety were independent predictors of use over time. In men, independent 
predictors included 3 or more co-morbid medical conditions for anxiolytics use, getting influenza 
vaccine for antidepressants use and poor/fair self-rated health for use of both medication classes. 
In women, independent predictors included a family income of $25,000 or less for anxiolytics 
use, and anxiety and depression for antidepressants use. 
Our findings are consistent with one longitudinal community-based study that reported 
increasing trend in use of SSRIs and TCAs from 1986-1987 to 1996-1997.(D. G. Blazer et al., 
2000) However, data from that same sample showed reduction in benzodiazepine use from 12% 
to 10.2% over ten years of follow-up.(D. Blazer et al., 2000) Another longitudinal community-
based study showed that benzodiazepine use remained stable between 1982 and 1988.(Dealberto, 
Seeman, et al., 1997) Our study presents more recent information on the trend of anxiolytic 
medication use in community-dwelling older adults. Our findings regarding significant 
predictors of anxiolytic and antidepressant medications use in community-dwelling older adults 
are consistent with these longitudinal studies in terms of Caucasian race, depression and self-
rated health, but not regarding greater medical co-morbidity. Our study extends this evidence to 
include anxiety, functional limitation and family income, and identifies which predictors that are 
potentially gender-specific. 
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Several consumer and care provider factors may explain the observed increase in use of 
anxiolytic and antidepressant medications in older adults.(Mojtabai & Olfson, 2014; Olfson et 
al., 2015) Consumer factors may include increased rate of mental health problems that might 
have necessitated prescription; change of attitudes toward mental health problems that might 
have increased healthcare seeking for previously underreported mental health problems; and 
advertising of psychotropic medications that might have increased requests for prescriptions. 
Provider factors may include improved detection and diagnosis of mental health problems that 
might have increased prescribing; limited access or unavailability of alternative effective 
evidence based treatments, such as psychotherapy, that might have necessitated pharmacotherapy 
as the sole option; and lack of specialized knowledge regarding risk-benefit ratio of medication 
use in older adults that might have resulted in increased inappropriate prescribing. However, we 
cannot confirm the impact of these factors, if any, as we did not measure them. It is important to 
note that a nationally representative survey reported that mood and anxiety disorders declined 
with age (Byers et al., 2010), which may indicate that true increase of these mental health 
problems over time is unlikely. In our sample, prevalence of potential indications, such as 
anxiety and depression, was generally higher than prevalence of anxiolytic and antidepressant 
medication use, which may point toward existing but undertreated problems. However, such 
conclusion should take into account that anxiety and depression were not clinically assessed in 
our study. 
Various hypotheses may explain the different level of psychotropic medication use 
between men and women.(Voyer et al., 2004) Most of these hypotheses pertain to women and 
include: women are more likely to report their psychological problems, request prescriptions 
explicitly, and hold positive views about psychotropic medications. In men, preferring alcohol 
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use to deal with psychological problems is one hypothesis. We could only directly explore the 
alcohol-medicating hypothesis, as we did not measure the other factors pertaining to women. In 
our study, some predictors of anxiolytic and antidepressant medications use were significant in 
one gender and not the other.  While statistical tests for gender differences were not significant, 
these findings may potentially indicate different healthcare seeking behavior for men and 
women. Men may not directly seek treatment for their mental health problems, but rather get 
anxiolytic or antidepressant medications while under care for other issues (as denoted by factors 
such as medical co-morbidity and getting influenza vaccine). Women may be more explicit about 
their mental health problems and request treatment with anxiolytic or antidepressant medications 
(as denoted by factors such as anxiety and depression). However, this explanation is likely 
speculative and needs confirmation by future studies. 
Strengths of this study include the longitudinal design over ten years of follow-up, a 
large, well-characterized cohort of older community-dwelling adults, and medication data 
collection that is based on actual medication use by participants rather than medical, pharmacy or 
administrative records. This study has several limitations. First, the sample included relatively 
healthy older adults living in two states in the United States and, therefore, may not be 
representative of other population groups elsewhere. Second, we did not assess the clinical 
reasons for which these medications were prescribed; however, we measured several potential 
indications such as anxiety, depression, sleep problems and pain. Third, we did not have data on 
characteristics of primary care providers including prescribing behavior, which are important 
factors for medication use. 
Our findings suggest that the use of anxiolytic and antidepressant medications is 
increasing in community-dwelling older adults and may have gender-specific predictors. Future 
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studies should investigate the risk-benefit ratio for using these medications in the oldest old men 
and women. Future studies, particularly related to prescribing practices and provider education, 
should explore potential gender differences in the healthcare seeking behavior in the oldest old. 
47 
3.6 TABLES 
Table 3.1 Baseline characteristics of users and non-users of anxiolytic medications by gender 
Characteristics 
Total 
N = 3,055 
Men 
N = 1,481 
Women 
N = 1,574 
Non-users 
N = 1,416 
Users 
N = 65 
p-value Non-users 
N = 1,466 
Users 
N = 108 
p-value 
Demographics 
Age (years), mean ± SD 73.63 
± 2.87 
73.76 ± 
2.88 
73.91 ± 
2.73 
0.7 73.54 
± 2.88 
73.05   
± 2.75 
0.09 
Race (African-American), 
n (%) 1,266 
(41.44) 
527 
(37.22) 
16 
(24.62) 
0.04 681 
(46.45) 
42 
(38.89) 
0.13 
Education (less than high 
school), n (%) 
766 
(25.14) 
384 
(27.16) 
18 
(27.69) 
0.9 335 
(22.95) 
29 
(26.85) 
0.4 
Marital status (married), n 
(%) 
1,568 
(54.81) 
972 
(72.38) 
53 
(85.48) 
0.02 510 
(37.61) 
33 
(33.00) 
0.4 
Family income ($25,000 or 
less), n (%) 
1,402      
(52.24) 
550 
(42.97) 
26 
(44.07) 
0.9 757 
(60.56) 
69 
(72.63) 
0.02 
Clinic site (Pittsburgh), n 
(%) 
1,516 
(49.62) 
715 
(50.49) 
21 
(32.31) 
0.004 732 
(49.93) 
48 
(44.44) 
0.3 
Health status 
Self-rated health 
(poor/fair), n (%) 
493 
(16.16) 
220 
(15.55) 
23 
(35.38) 
<0.001 227 
(15.52) 
23 
(21.30) 
0.1 
Co-morbid medical 
conditions (3 or more), n 
(%) 
520 
(18.20) 
239 
(18.16) 
22 
(37.29) 
<0.001 237 
(17.15) 
22 
(22.00) 
0.2 
Limitation due to hearing 
problems, n (%) 
269 
(8.88) 
173 
(12.33) 
8 
(12.31) 
1.0 76 
(5.23) 
12 
(11.21) 
0.01 
Limitation due to vision 
problems, n (%) 
268 
(8.79) 
137 
(9.70 
2 
(3.08) 
0.08 118 
(8.05) 
11 
(10.19) 
0.4 
IADL limitations (any), n 
(%) 
372 
(14.63) 
94 
(8.30) 
10 
(18.52) 
0.01 240 
(19.00) 
28 
(29.79) 
0.01 
BMI, mean ± SD 27.40 
± 4.82 
27.11    
3.98 
26.24    
3.46 
0.08 27.75    
5.53 
27.15    
4.97 
0.3 
Any bodily pain, n (%) 1,999      
(65.50) 
842 
(59.55) 
46 
(70.77) 
0.07 1,020 
(69.62) 
91 
(84.26) 
<0.01 
Poor sleep, n (%) 344 
(11.33) 
142 
(10.06) 
7 
(10.77) 
0.9 174 
(11.99) 
21 
(19.44) 
0.02 
Anxiety, n (%) 430 
(14.18) 
149 
(10.58) 
15 
(23.08) 
0.002 222 
(15.29) 
44 
(41.12) 
<0.001 
Depression, n (%) 144 
(4.75) 
51 
(3.63) 
5 
(7.81) 
0.09 72 
(4.95) 
16 
(14.95) 
<0.001 
3MS (score), mean ± SD 90.07 
± 8.40 
89.57 
± 8.56 
88.32 
± 10.60 
0.6 90.64 
± 8.15 
89.88 
± 7.63 
0.2 
Life style 
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Smoking status, n (%) 0.2 0.6 
   Current 316 
(10.36) 
153 
(10.83) 
6 
(9.23) 
147 
(10.04) 
10 
(9.26) 
   Former 1,397 
(45.80) 
838 
(59.31) 
46 
(70.77) 
473 
(32.31) 
40 
(37.04) 
   Never 1,337 
(43.84) 
422 
(29.87) 
13 
(20.00) 
844 
(57.65) 
58 
(53.70) 
Alcohol use, n (%) 0.2 0.8 
   Current 1,505 
(49.49) 
813 
(57.78) 
30 
(46.88) 
615 
(42.07) 
47 
(43.52) 
   Former 677 
(22.26) 
362 
(25.73) 
20 
(31.25) 
277 
(18.95) 
18 
(16.67) 
   Never 859 
(28.25) 
232 
(16.49) 
14 
(21.88) 
570 
(38.99) 
43 
(39.81) 
Healthcare 
Primary care provider, n 
(%) 
2,878 
(94.48) 
1,323 
(93.63) 
65 
(100.00) 
0.03 1,384 
(94.73) 
106 
(99.07) 
0.06 
Supplemental health 
insurance for medications, 
n (%) 
1,883 
(63.02) 
868 
(62.63) 
40 
(61.54) 
0.9 905 
(63.24) 
70 
(66.04) 
0.6 
Influenza vaccine in the 
past year, n (%) 
2,103 
(69.13) 
996 
(70.69) 
48 
(73.85) 
0.6 983 
(67.33) 
76 
(70.37) 
0.5 
Table 3.1 Continued 
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Table 3.2 Baseline characteristics of users and non-users of antidepressant medications by gender 
Characteristics  
Total 
N = 3,055 
Men 
N = 1,481 
Women 
N = 1,574 
Non-users 
N = 1,424 
Users 
N = 57 
p-value Non-users 
N = 1,461 
Users 
N = 113 
p-value 
Demographics 
Age (years), mean ± SD 73.63 
± 2.87 
73.77 
± 2.88 
73.77 
± 2.56 
0.9 73.52 
± 2.87 
73.22 
± 2.84 
0.3 
Race (African-American), 
n (%) 
1,266 
(41.44) 
526 
(36.94) 
17 
(29.82) 
0.3 690 
(47.23) 
33 
(29.20) 
<0.001 
Education (less than high 
school), n (%) 
766 
(25.14) 
387 
(27.22) 
15 
(26.32) 
0.9 347 
(23.83) 
17 
(15.18) 
0.04 
Marital status (married), n 
(%) 
1,568 
(54.81) 
 
979 
(72.52) 
46 
(83.64) 
0.07 498 
(36.83) 
45 
(43.27) 
0.2 
Family income ($25,000 or 
less), n (%) 
1,402       
(52.24) 
554 
(43.18) 
22 
(39.29) 
0.6 768 
(61.64) 
58 
(58.59) 
0.5 
Clinic site (Pittsburgh), n 
(%) 
1,516 
(49.62) 
715 
(50.21) 
21 
(36.84) 
0.05 721 
(49.35) 
59 
(52.21) 
0.6 
Health status 
Self-rated health 
(poor/fair), n (%) 
493 
(16.16) 
227 
(15.95) 
16 
(28.07) 
0.02 229 
(15.71) 
21 
(18.58) 
0.4 
Co-morbid medical 
conditions (3 or more), n 
(%) 
520 
(18.20) 
246 
(18.58) 
15 
(29.41) 
0.05 236 
(17.14) 
23 
(21.90) 
0.2 
Limitation due to hearing 
problems, n (%) 
269 
(8.88) 
175 
(12.40) 
6 
(10.53) 
0.7 77 
(5.31) 
11 
(9.91) 
0.04 
Limitation due to vision 
problems, n (%) 
268 
(8.79) 
131 
(9.23) 
8 
(14.04) 
0.2 119 
(8.15) 
10 
(8.85) 
0.8 
IADL limitations (any), n 
(%) 
372 
(14.63) 
96 
(8.41) 
8 
(18.18) 
0.02 239 
(18.91) 
29 
(31.18) 
<0.01 
BMI, mean ± SD 27.40 
± 4.82 
27.08       
± 3.91 
26.73 
± 5.11 
0.5 27.75 
± 5.54 
27.25 
± 4.86 
0.4 
Any bodily pain, n (%) 1,999       
(65.50) 
852 
(59.92) 
36 
(63.16) 
0.6 1,025 
(70.21) 
86 
(76.11) 
0.2 
Poor sleep, n (%) 344 
(11.33) 
143 
(10.08) 
6 
(10.53) 
0.9 172 
(11.88) 
23 
(20.72) 
0.01 
Anxiety, n (%) 430 
(14.18) 
152 
(10.73) 
12 
(21.43) 
0.01 232 
(16.02) 
34 
(30.63) 
<0.001 
Depression, n (%) 144 
(4.75) 
52 
(3.67) 
4 
(7.27) 
0.2 70 
(4.83) 
18 
(16.22) 
<0.001 
3MS (score), mean ± SD 90.07 
± 8.40 
89.52 
± 8.70 
89.25 
± 7.56 
0.5 90.56 
± 8.18 
90.94 
± 7.26 
0.9 
Life style 
Smoking status, n (%)    0.1   0.6 
   Current  316 
(10.36) 
149 
(10.49) 
10 
(17.54) 
 143 
(9.80) 
14 
(12.39) 
 
   Former 1,397 
(45.80) 
849 
(59.75) 
35 
(61.40) 
 480 
(32.90) 
33 
(29.20) 
 
   Never 1,337 
(43.84) 
423 
(29.77) 
12 
(21.05) 
 836 
(57.30) 
66 
(58.41) 
 
Alcohol use, n (%)    0.2   0.8 
   Current 1,505 
(49.49) 
817 
(57.74) 
26 
(46.43) 
 611 
(41.94) 
51 
(45.13) 
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   Former 677 
(22.26) 
363 
(25.65) 
19 
(33.93) 
274 
(18.81) 
21 
(18.58) 
   Never 859 
(28.25) 
235 
(16.61) 
11 
(19.64) 
572 
(39.26) 
41 
(36.28) 
Healthcare 
Primary care provider, n 
(%) 
2,878 
(94.48) 
1,331 
(93.67) 
57 
(100.00) 
0.05 1,381 
(94.91) 
109 
(96.46) 
0.7 
Supplemental health 
insurance for medications, 
n (%) 
1,883 
(63.02) 
873 
(62.63) 
35 
(61.40) 
0.9 901 
(63.23) 
74 
(66.07) 
0.5 
Influenza vaccine in the 
past year, n (%) 
2,103 
(69.13) 
995 
(70.22) 
49 
(85.96) 
0.01 981 
(67.33) 
78 
(70.27) 
0.5 
Table 3.2 Continued
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Table 3.3 Proportion of anxiolytic and antidepressant medications users by gender for each visit 
Medication class Baseline 
N = 3,055 
Year 6 
N = 2,515 
Year 11 
N = 1,337 
p for trend 
BZDs, n (%) 
   Men 51 (1.67) 49 (1.95) 36 (2.69) 0.01 
   Women 83 (2.72) 71 (2.82) 54 (4.04) 0.04 
NBZDs, n (%) 
   Men 15 (0.49) 5 (0.20) 12 (0.90) 0.09 
   Women 28 (0.92) 15 (0.60) 16 (1.20) 0.4 
SNRIs, n (%) 
   Men 2 (0.07) 5 (0.20) 6 (0.45) 0.02 
   Women 1 (0.03) 4 (0.16) 11 (0.82) <0.01 
SSRIs, n (%) 
   Men 28 (0.92) 68 (2.70) 45 (3.37) <0.001 
   Women 57 (1.87) 106 (4.21) 59 (4.41) <0.001 
TCAs, n (%) 
   Men 29 (0.95) 16 (0.64) 4 (0.30) 0.04 
   Women 57 (1.87) 35 (1.39) 22 (1.65) 0.5 
Total* 
   Men 110 (3.60) 128 (5.09) 85 (6.36) <0.001 
   Women 202 (6.61) 204 (8.11) 141 (10.55) <0.001 
*Total is less than sum of individual classes as some participants were taking multiple medications.
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Table 3.4 Predictors of anxiolytic and antidepressant medications in the full sample 
Anxiolytic medications Antidepressant medications 
Univariable Multivariable* Univariable Multivariable* 
Odds Ratio (95% Confidence Interval) 
Gender 
   Female 1.44 (1.12, 1.86) 1.55 (1.24, 1.94) 1.63 (1.20, 2.22) 
   Male 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Age (years) 0.98 (0.94, 1.02) 0.99 (0.95, 1.03) 
Race 
   African-
American 
0.62 (0.47, 0.80) 0.59 (0.41, 0.86) 0.51 (0.40, 0.64) 0.48 (0.35, 0.65) 
   Caucasian 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Education 
   Less than high 
school 
1.07 (0.80, 1.42) 0.78 (0.59, 1.02) 
   High school or 
more 
1.00 (reference) 1.00 (reference) 
Marital status 
   Married 0.99 (0.77, 1.26) 0.92 (0.74, 1.14) 
   Not married 1.00 (reference) 1.00 (reference) 
Family income 
   $25,000 or less 1.18 (0.91, 1.53) 1.48 (1.03, 2.12) 0.90 (0.72, 1.14) 
   More than 
$25,000 
1.00 (reference) 1.00 (reference) 1.00 (reference) 
Self-rated health 
   Poor/fair 1.71 (1.34, 2.19) 1.28 (1.02, 1.61) 
   Good/excellent 1.00 (reference) 1.00 (reference) 
Co-morbid medical 
conditions  
   3 or more 1.69 (1.25, 2.29) 1.78 (1.22, 2.61) 1.34 (1.02, 1.77) 
   0-2 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Limitation due to 
hearing problems 
   Yes 1.23 (0.81, 1.85) 1.31 (0.93, 1.86) 
   No 1.00 (reference) 1.00 (reference) 
Limitation due to 
vision problems 
   Yes 0.74 (0.45, 1.22) 1.22 (0.85, 1.75) 
   No 1.00 (reference) 1.00 (reference) 
IADL limitations 
   Any 1.76 (1.27, 2.45) 1.69 (1.12, 2.55) 2.24 (1.69, 2.98) 1.86 (1.31, 2.65) 
   None 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
BMI 0.98 (0.96, 1.01) 1.00 (0.98, 1.02) 
Any bodily pain 
   Yes 1.64 (1.23, 2.19) 1.46 (1.14, 1.86) 
   No 1.00 (reference) 1.00 (reference) 
Poor sleep 
   Yes 1.30 (0.91, 1.86) 1.53 (1.13, 2.08) 
   No 1.00 (reference) 1.00 (reference) 
Anxiety 
   Yes 2.43 (1.82, 3.23) 2.31 (1.64, 3.26) 2.18 (1.69, 2.82) 1.54 (1.13, 2.10) 
   No 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Depression 
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   Yes 1.91 (1.43, 2.57) 2.29 (1.76, 2.96) 2.25 (1.55, 3.25) 
  No 1.00 (reference) 1.00 (reference) 1.00 (reference) 
3MS (score) 0.98 (0.97, 1.00) 1.00 (0.99, 1.02) 
Smoking status 
   Current 1.24 (0.78, 1.98) 1.23 (0.78, 1.94) 
   Former 1.17 (0.89, 1.54) 0.89 (0.68, 1.15) 
   Never 1.00 (reference) 1.00 (reference) 
Alcohol use 
   Current 0.72 (0.53, 0.99) 0.95 (0.71, 1.28) 
   Former 0.97 (0.70, 1.34) 0.83 (0.60, 1.17) 
   Never 1.00 (reference) 1.00 (reference) 
Primary care 
provider 
   Yes 2.42 (1.18, 5.00) 3.43 (1.21, 9.72) 3.18 (1.44, 7.02) 
   No 1.00 (reference) 1.00 (reference) 
Supplemental 
health insurance 
for medications 
   Yes 0.93 (0.72, 1.19) 1.05 (0.84, 1.32) 
   No 1.00 (reference) 1.00 (reference) 
Influenza 
vaccine in the 
past year 
   Yes 1.26 (0.95, 1.68) 1.55 (1.19, 2.02) 
   No 1.00 (reference) 1.00 (reference) 
*Adjusted for clinic site.
Table 3.4 Continued
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Table 3.5 Predictors of anxiolytic medications use by gender 
Men Women 
Univariable Multivariable* Univariable Multivariable* 
Odds Ratio (95% Confidence Interval) 
Age (years) 1.03 (0.96, 1.10) 0.95 (0.90, 1.01) 
Race 
  African-American 0.53 (0.33, 0.83) 0.50 (0.29, 0.85) 0.63 (0.45, 0.87) 0.60 (0.39, 0.91) 
   Caucasian 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Education 
   Less than high 
school 
0.98 (0.63, 1.53) 1.17 (0.81, 1.70) 
   High school or 
more 
1.00 (reference) 1.00 (reference) 
Marital status 
   Married 1.85 (1.20, 2.85) 0.86 (0.61, 1.22) 
   Not married 1.00 (reference) 1.00 (reference) 
Family income 
   $25,000 or less 0.91 (0.60, 1.39) 1.28 (0.90, 1.81) 1.84 (1.19, 2.85) 
   More than $25,000 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Self-rated health 
   Poor/fair 1.60 (1.09, 2.34) 2.06 (1.26, 3.37) 1.72 (1.25, 2.36) 
   Good/excellent 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Co-morbid medical 
conditions  
   3 or more 2.10 (1.32, 3.35) 1.92 (1.14, 3.21) 1.49 (1.00, 2.23) 
   0-2 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Limitation due to 
hearing problems 
   Yes 1.32 (0.75, 2.30) 1.35 (0.73, 2.50) 
   No 1.00 (reference) 1.00 (reference) 
Limitation due to 
vision problems 
   Yes 0.42 (0.17, 1.02) 1.01 (0.55, 1.84) 
   No 1.00 (reference) 1.00 (reference) 
IADL limitations 
   Any 2.19 (1.17, 4.12) 1.50 (1.02, 2.20) 
   None 1.00 (reference) 1.00 (reference) 
BMI 0.98 (0.94, 1.02) 0.98 (0.95, 1.01) 
Any bodily pain 
   Yes 1.50 (0.97, 2.31) 1.63 (1.10, 2.41) 
   No 1.00 (reference) 1.00 (reference) 
Poor sleep 
   Yes 0.93 (0.47, 1.86) 1.48 (0.97, 2.24) 
   No 1.00 (reference) 1.00 (reference) 
Anxiety 
   Yes 2.20 (1.34, 3.61) 1.93 (1.15, 3.24) 2.51 (1.75, 3.59) 2.40 (1.66, 3.48) 
   No 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Depression 
   Yes 1.64 (0.94, 2.85) 2.02 (1.44, 2.85) 
   No 1.00 (reference) 1.00 (reference) 
3MS (score) 0.99 (0.97, 1.01) 0.98 (0.97, 1.00) 
Smoking status 
   Current 1.81 (0.81, 4.07) 1.25 (0.68, 2.27) 
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   Former 2.00 (1.18, 3.42) 1.11 (0.78, 1.57) 
   Never 1.00 (reference) 1.00 (reference) 
Alcohol use 
   Current 0.90 (0.48, 1.69) 0.79 (0.54, 1.15) 
   Former 1.33 (0.72, 2.49) 0.95 (0.63, 1.43) 
   Never 1.00 (reference) 1.00 (reference) 
Primary care 
provider 
   Yes 3.71 (0.88, 15.60) 1.90 (0.82, 4.39) 
   No 1.00 (reference) 1.00 (reference) 
Supplemental health 
insurance for 
medications 
   Yes 1.04 (0.69, 1.58) 0.86 (0.62, 1.18) 
   No 1.00 (reference) 1.00 (reference) 
Influenza vaccine 
in the past year 
   Yes 1.20 (0.75, 1.94) 1.34 (0.94, 1.91) 
   No 1.00 (reference) 1.00 (reference) 
*Adjusted for clinic site.
Table 3.5 Continued
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Table 3.6 Predictors of antidepressant medications use by gender 
Men Women 
Univariable Multivariable* Univariable Multivariable* 
Odds Ratio (95% Confidence Interval) 
Age (years) 1.01 (0.96, 1.07) 0.98 (0.93, 1.03) 
Race 
   African-American 0.51 (0.34, 0.77) 0.42 (0.24, 0.73) 0.46 (0.34, 0.62) 0.50 (0.34, 0.72) 
   Caucasian 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Education 
   Less than high 
school 
0.87 (0.57, 1.33) 0.74 (0.52, 1.06) 
   High school or 
more 
1.00 (reference) 1.00 (reference) 
Marital status 
   Married 0.97 (0.68, 1.40) 1.12 (0.84, 1.51) 
   Not married 1.00 (reference) 1.00 (reference) 
Family income 
   $25,000 or less 0.68 (0.46, 0.99) 0.96 (0.71, 1.31) 
   More than $25,000 1.00 (reference) 1.00 (reference) 
Self-rated health 
   Poor/fair 1.51 (1.05, 2.15) 1.61 (1.04, 2.51) 1.17 (0.88, 1.57) 
   Good/excellent 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Co-morbid medical 
conditions  
   3 or more 1.44 (0.93, 2.23) 1.32 (0.92, 1.89) 
   0-2 1.00 (reference) 1.00 (reference) 
Limitation due to 
hearing problems 
   Yes 1.09 (0.65, 1.84) 2.03 (1.26, 3.27) 
   No 1.00 (reference) 1.00 (reference) 
Limitation due to 
vision problems 
   Yes 1.27 (0.71, 2.28) 1.21 (0.76, 1.92) 
   No 1.00 (reference) 1.00 (reference) 
IADL limitations 
   Any 1.90 (0.99, 3.62) 2.06 (1.01, 4.21) 2.15 (1.55, 2.99) 1.81 (1.22, 2.68) 
   None 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
BMI 1.03 (0.98, 1.08) 0.98 (0.96, 1.01) 
Any bodily pain 
   Yes 1.21 (0.84, 1.73) 1.56 (1.11, 2.19) 
   No 1.00 (reference) 1.00 (reference) 
Poor sleep 
   Yes 1.25 (0.74, 2.10) 1.64 (1.13, 2.40) 
   No 1.00 (reference) 1.00 (reference) 
Anxiety 
   Yes 2.51 (1.59, 3.97) 1.92 (1.42, 2.60) 1.48 (1.03, 2.14) 
   No 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Depression 
   Yes 1.77 (1.11, 2.83) 2.45 (1.80, 3.35) 2.67 (1.72, 4.16) 
   No 1.00 (reference) 1.00 (reference) 1.00 (reference) 
3MS (score) 1.00 (0.98, 1.02) 1.00 (0.99, 1.02) 
Smoking status 
   Current 2.15 (0.98, 4.69) 1.20 (0.68, 2.09) 
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   Former 1.62 (0.99, 2.66) 0.82 (0.58, 1.16) 
   Never 1.00 (reference) 1.00 (reference) 
Alcohol use 
   Current 1.17 (0.63, 2.19) 1.11 (0.78, 1.57) 
   Former 1.20 (0.62, 2.31) 0.86 (0.57, 1.31) 
   Never 1.00 (reference) 1.00 (reference) 
Primary care 
provider 
   Yes 8.41 (1.18, 60.18) 2.19 (0.91, 5.25) 
   No 1.00 (reference) 1.00 (reference) 
Supplemental health 
insurance for 
medications 
   Yes 0.94 (0.65, 1.34) 1.13 (0.85, 1.52) 
   No 1.00 (reference) 1.00 (reference) 
Influenza vaccine in 
the past year 
   Yes 1.97 (1.26, 3.07) 1.97 (1.09, 3.56) 1.42 (1.02, 1.98) 
   No 1.00 (reference) 1.00 (reference) 1.00 (reference) 
*Adjusted for clinic site.
Table 3.6 Continued
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4.0  PAPER 2: ANXIETY SYMPTOMS AND RISK OF DEMENTIA AND MILD 
COGNITIVE IMPAIRMENT IN THE OLDEST OLD WOMEN 
4.1 ABSTRACT 
Background: Research investigating anxiety as a predictor of future cognitive decline in older 
adults is limited and findings conflict. We examined the relationship between level and changes 
of anxiety symptoms, and subsequent dementia and mild cognitive impairment (MCI) in the 
oldest old women. Methods: We studied 1,425 community-dwelling oldest old women (mean 
age = 82.8, SD ±3.1 years) who were followed on average for 4.9 years. The Goldberg Anxiety 
Scale was used to assess anxiety symptoms at baseline, and an expert clinical panel adjudicated 
dementia and MCI at follow-up. Participants with probable cognitive impairment (Mini-Mental 
State Examination score < 24, self-reported dementia diagnosis and use of medication) at 
baseline were excluded. Results: At baseline, there were 190 (13%) women who had 
moderate/severe anxiety symptoms and 403 (28%) who had mild anxiety symptoms. Women 
with mild or moderate/severe anxiety symptoms were more likely to also have depressed mood, 
poor sleep, more chronic medical conditions and more impairments in daily living activities 
compared to those with no anxiety symptoms. Compared to those with no anxiety symptoms at 
baseline, women with mild anxiety symptoms were more likely to develop dementia at follow-up 
(adjusted odds ratio = 1.66, 95% confidence interval 1.12, 2.45). No significant association was 
 59 
observed between anxiety symptoms and MCI. Conclusion: In the oldest old women, our 
findings suggest that mild and unstable anxiety symptoms may predict future risk of dementia, 
but not MCI. Future studies should explore potential underlying biological mechanisms linking 
these unique characteristics of anxiety to cognitive impairment. 
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4.2 INTRODUCTION 
In the United States, a nationally representative survey, the National Comorbidity Survey 
Replication, estimated the lifetime prevalence of any anxiety disorder as 16.6% and 9.6% among 
women and men aged 65 years and older, respectively.(Gum et al., 2009) Another nationally 
representative study, the Aging, Demographics and Memory Study, reported the prevalence of 
dementia as 16% and 11% among women and men aged 70 years and older, 
respectively.(Plassman et al., 2007) Both conditions have been related to several adverse health 
outcomes including increased disability and mortality.(WHO, 2012; Wolitzky-Taylor et al., 
2010) 
Multiple lines of evidence support a significant association between both conditions. 
First, cross-sectional studies documented lower cognitive function in older adults with 
heightened anxiety (Beaudreau & O'Hara, 2009; Bierman et al., 2005; Mantella et al., 2007; 
Wetherell et al., 2002), and elevated anxiety symptoms in older adults with cognitive 
impairment.(Andreescu et al., 2014; Geda et al., 2008; Lopez et al., 2003; Lyketsos et al., 2002) 
Second, longitudinal studies suggested that anxiety increased the risk of progression of mild 
cognitive impairment (MCI) to dementia.(Gallagher et al., 2011; Palmer et al., 2007) Third, a 
number of studies reported that the use of benzodiazepines, a class of anxiolytic medications, 
was associated with risk of cognitive impairment or decline.(Billioti de Gage et al., 2012; 
Gallacher et al., 2012; Lagnaoui et al., 2002; Paterniti et al., 2002)  This may indicate that 
benzodiazepine use is a marker of an underlying condition, such as anxiety, that led to the 
reported association.(Yaffe & Boustani, 2014) Finally, there is a high co-occurrence between 
 61 
anxiety and depression(Byers et al., 2010; Kessler et al., 2003), which itself is a potential risk 
factor for cognitive impairment.(Byers & Yaffe, 2011; Ganguli, 2009)  
The longitudinal relationship between anxiety and subsequent cognitive impairment in 
older adults remains unclear.(Beaudreau & O'Hara, 2008) Previous research examining this 
relationship was inconclusive, and was limited by small sample size, short follow-up, not 
accounting for important confounders and measurement issues.(Bierman et al., 2008; Burton et 
al., 2013; Cherbuin et al., 2009; de Bruijn et al., 2014; Gallacher et al., 2009); Okereke and 
Grodstein (2013); (Pietrzak et al., 2012; Potvin, Forget, et al., 2011; Sinoff & Werner, 2003) 
Finally, previous studies did not investigate how specific characteristics of anxiety are related to 
each level of cognitive impairment. Therefore, additional research is needed to understand the 
role of anxiety as a predictor of future cognitive impairment and whether anxiety can early 
identify those at higher risk or is a potentially modifiable risk factor. 
Anxiety disorders are more prevalent in women than men and have been associated with 
more disability in women than men.(Byers et al., 2010) (Baxter et al., 2014) Therefore, it is 
important to examine the relationship between anxiety and cognitive impairment separately for 
men and women. We are not aware of any prospective study that focused on the oldest old 
women (age 80 and above), the fastest growing segment of the population in the United States. 
(U.S.CensusBureau, 2014) 
In this longitudinal study, we examined the association between presence, level and 
changes of anxiety symptoms and risk of subsequent dementia, MCI and decline in cognitive 
functioning among oldest old women enrolled in the Study of Osteoporotic Fractures. We 
hypothesized that severe and persistent anxiety symptoms will be associated with increased risk 
of dementia, MCI and poor cognitive function. 
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4.3 METHODS 
4.3.1 Population 
We utilized data from the Study of Osteoporotic Fractures (SOF)(Cummings et al., 1995), a 
prospective cohort study of community-dwelling women aged 65 years and older in 1986-1988 
(SOF visit 1). In brief, 9,704 predominantly Caucasian older women were recruited from 
population-based listings in 4 locations in the United States as follows: Baltimore, 
Maryland; Minneapolis, Minnesota; Monongahela Valley (near Pittsburgh), Pennsylvania; and 
Portland, Oregon. An additional 662 African-American older women were recruited during SOF 
visit 6 (1997-1998). Women were not enrolled in SOF if they were unable to walk 
without assistance or had undergone a bilateral hip replacement. The institutional review board 
at each site approved the study and participants provided written informed consent.  
At SOF visit 9, 1,513 women from 3 of the 4 original SOF sites attended a clinic visit for 
a cognitive status assessment, and therefore participants from only those 3 sites were part of our 
study. For this study, we included 1,470 women (40% of survivors in participating sites) who 
had anxiety assessment at SOF visit 8 (2002-2004; baseline) and had cognitive status assessment 
at SOF visit 9 (2006-2008; follow-up). Of those 1,470 women with complete exposure and 
outcome data, we excluded 17 women with indeterminate cognitive status at follow-up. We 
additionally excluded 28 women with probable cognitive impairment at baseline, with the 
following overlapping criteria: self-report of dementia diagnosis (n = 4); self-report of dementia 
treatment (n = 5); and a Mini-Mental State Examination (MMSE)(Folstein, Folstein, & McHugh, 
1975) score < 24 (n = 19). In total, 1,425 women constituted the analytical sample for our study. 
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4.3.2 Measurement of anxiety symptoms 
At the baseline and follow-up visits, anxiety symptoms were measured using the Goldberg 
Anxiety Scale (GAS).(Goldberg et al., 1988) GAS is a 9-item self-report instrument that inquires 
about anxiety symptoms experienced in the past month. GAS items span various types of anxiety 
symptoms, and are rated as yes (1) or no (0) answers with a total score ranging from 0 to 9. 
Participants must answer yes to at least 2 of the first 4 items in order to have the subsequent 5 
items included in their total score. The 4 screening items are as follows: being keyed up or on 
edge; worrying a lot; being irritable, and having difficulty relaxing. The recommended cutoff 
score of 5 suggests that a participant has a 50% chance of a clinically significant anxiety, while 
higher scores substantially increase the probability of a significant anxiety disturbance.  
To study the level of anxiety symptoms, we classified participants according to baseline 
GAS score into the following 3 groups: no anxiety (0), mild anxiety (1-4), and moderate/severe 
anxiety (5-9). To study the change of anxiety symptoms over time, we classified participants 
according to baseline and follow-up GAS scores into the following 4 groups: never anxious (0 at 
baseline and follow-up), incident anxiety (0 at baseline and ≥ 5 at follow-up), persistent anxiety 
(≥ 5 at baseline and follow-up), and receded anxiety (≥ 5 at baseline and 0 at follow-up). To 
capture large changes over time, these 4 groups covered changes between both extremes of 
anxiety symptoms level (no symptoms versus moderate/severe symptoms), and as such they 
constituted only a subsample (N = 641) that did not include those with mild anxiety symptoms 
(Figure 4.6.1).  
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4.3.3 Measurement of clinical cognitive status 
At the follow-up visit, a diagnosis of dementia or MCI was determined using a two-stage 
process. First, participants were screened for cognitive impairment according to one or more of 
the following 5 criteria: score < 88 on the Modified Mini-Mental State Examination (3MS)(Teng 
& Chui, 1987); score < 4 on the California Verbal Learning Test, Second Edition (CVLT-II) 
delayed recall(Delis, Kramer, Kaplan, & Ober, 2000); score ≥ 3.6 on the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE)(Jorm & Jacomb, 1989); self-report 
of dementia diagnosis; or nursing home residence. Those who screened negative on all of the 
above were considered as having normal cognition, while a panel of clinical experts adjudicated 
those who screened positive on one or more of the above. The panel consisted of a 
geropsychologist, a neurologist and two neuropsychologists, who considered the following 
information for each participant: neuropsychological test scores; depression score; functional 
status; medications, and medical history. Diagnoses of dementia and MCI were made according 
to DSM-IV criteria (American Psychiatric Association, 2000) and modified 
Petersen criteria (Petersen et al., 2001), respectively. Further details about the above clinical 
adjudication process have been published elsewhere.(Yaffe et al., 2011) 
4.3.4 Measurement of cognitive function 
At the baseline and follow-up visits, a shorter version of the MMSE (in which questions 
regarding language were left out) was administered.(Yaffe et al., 2011) The short MMSE scores 
ranged from 0 to 26, with lower scores indicating poorer cognitive function. Clinically 
significant cognitive decline was defined as the change in short MMSE score of at least one 
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standard deviation from mean change from baseline to follow-up. This difference was equivalent 
to a loss of 3.33 or more MMSE points over time. The reference group included participants who 
declined less than one standard deviation, those who maintained their scores and those with 
improved scores.  
At the follow-up visit, an expanded neuropsychological test battery was administered to 
participants. Tests included the 3MS, the Trails B(Reitan & Wolfson, 1985), the CVLT-II with 
immediate and 10-minute delay scores, Digit Span with forward and backward scores(Wechsler, 
1997), and verbal fluency tests(Spreen & Strauss, 1991). Tests assessed multiple cognitive 
domains including global cognition (3MS), executive function and psychomotor speed (Trails 
B), verbal learning and memory (CVLT-II), attention (forward Digit Span), working memory 
(backwards Digit Span), phonemic fluency (naming as many words beginning with “f”), and 
category fluency (naming as many vegetables).  
4.3.5 Other measurements 
At the baseline visit, additional measurements were collected via self-report questionnaires. 
Demographic information included age, education, race and marital status. Medical history was 
defined as prior physician diagnosis of select medical conditions. Participants reported smoking 
status, alcohol use, caffeine intake, whether or not the participant walked for exercise, and self-
rated health status. Functional status was assessed by collecting information on difficulty with 6 
instrumental activities of daily living (IADL), which included walking 2 to 3 blocks on level 
ground, climbing up to 10 steps, walking down 10 steps, preparing meals, doing heavy 
housework, and shopping for groceries or clothing. The number of activities that were difficult 
was summed for a total IADL score. The Geriatric Depression Scale (GDS)(Lyness et al., 1997) 
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was used to assess depressive symptoms, with the standard cutoff score of 6 or more used to 
define depression. The Pittsburgh Sleep Quality Index (PSQI)(Buysse, Reynolds, Monk, 
Berman, & Kupfer, 1989) was used to assess sleep, with the standard cutoff score of 5 or more 
used to define poor sleep. Medication use was ascertained by asking participants to bring all 
current prescription and non-prescription medications used in the past month to their clinic visits, 
while an interviewer collected this information in home visits. Medications were coded and 
categorized using the Iowa Drug Information Service (IDIS) scheme.(Pahor et al., 1994)  
4.3.6 Statistical analysis 
We calculated descriptive statistics for all variables and compared participants by level of 
anxiety symptoms at baseline and by clinical cognitive status at follow-up. For these 
comparisons, we used chi-squared test (or Fisher's exact test for low expected cell counts) for 
categorical variables, one-way ANOVA for normally distributed continuous data and the Kruskal 
Wallis test for skewed continuous data. Next, a series of unadjusted and multivariable-adjusted 
logistic regression models of the relationship between anxiety symptoms, and dementia and MCI 
were fit. Similarly, linear regression models were fit for cognitive function tests. Based on 
literature (Zeki Al Hazzouri et al., 2014), multivariable models were adjusted for the following 
potential confounders: demographics (age, education and marital status), health behaviors 
(smoking, alcohol use and exercise), medical history (hypertension, myocardial infarction, 
stroke, and diabetes), psychotropic medications (benzodiazepine, non-benzodiazepine non-
barbiturate sedative hypnotic and antidepressant), depression and poor sleep. All statistical 
analyses were conducted with Stata version 13.1 (StataCorp LP, College Station, TX, USA). 
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4.4 RESULTS 
4.4.1 Characteristics of participants 
Baseline characteristics of participants are presented in Tables 4.6.1 and 4.6.2. At baseline (mean 
age = 82.8 years), there were 190 (13%) women who had moderate/severe anxiety symptoms and 
403 (28%) who had mild anxiety symptoms. Women with moderate/severe or mild anxiety 
symptoms at baseline were more likely to be married, have depressed mood and poor sleep, take 
more psychotropic medications, suffer from more chronic medical conditions, and have more 
impairments in daily living activities compared to those with no anxiety symptoms. After mean 
follow-up time of 4.9 (standard deviation [SD] ±0.6) years, 233 (16%) women developed 
dementia and 335 (24%) women developed MCI. Women with dementia or MCI at follow-up 
were more likely to be older, have high school education or less, have depressed mood, take 
more antidepressants, exercise less and have more impairments in daily living activities 
compared to those who maintained normal cognition.  
4.4.2 Anxiety symptoms and clinical cognitive status 
The models of clinical cognitive status by anxiety symptoms are presented in Table 4.6.3. 
Women with mild anxiety symptoms at baseline were 1.58 times more likely to develop 
dementia at follow-up compared to those with no anxiety symptoms at baseline. This association 
remained statistically significant after controlling for potential confounding factors with a 
multivariable-adjusted odds ratio [OR] of 1.66 (95% confidence interval [CI] 1.12, 2.45).  
Moderate/severe anxiety symptoms, however, were not significantly associated with risk of 
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dementia (multivariable-adjusted OR = 1.27, 95% CI 0.71, 2.28). Overall, anxiety remained a 
significant predictor of dementia in the multivariable-model (Wald (2) = 6.34, p = 0.04). There 
were also no significant association between any level of anxiety symptoms and risk of MCI.  
Women who had moderate/severe anxiety symptoms at baseline and did not have any 
anxiety symptoms at follow-up (receded anxiety) were 3.80 times more likely to develop 
dementia at follow-up compared to those who were never anxious. Similarly, women who did 
not have any anxiety symptoms at baseline and developed moderate/severe anxiety symptoms at 
follow-up (incident anxiety) were 1.85 times more likely to develop dementia at follow-up 
compared to those who were never anxious. However, this association did not remain significant 
after controlling for potential confounding factors (multivariable-adjusted OR = 1.54, 95% CI 
0.74, 3.20). Persistent anxiety symptoms over time were not significantly associated with 
dementia. There were no significant association between any change of anxiety symptoms over 
time and risk of MCI. 
Examining a curvilinear relationship between anxiety symptoms and cognitive 
impairment revealed a significant quadratic term for anxiety score and odds of developing 
dementia (Figure 4.6.2), but not MCI.  
4.4.3 Anxiety symptoms and cognitive function tests 
The models of cognitive function tests by anxiety symptoms are presented in Table 4.6.4. 
Compared to women with no anxiety symptoms at baseline, those with mild anxiety symptoms at 
baseline performed significantly worse on tests for verbal learning and memory (CVLT-II) and 
working memory (Backwards Digits Span). Those with moderate/severe anxiety symptoms 
performed significantly worse only on category fluency test.  
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Compared to women who were never anxious, those with receded anxiety symptoms 
performed significantly worse on 3MS (4.98 points reduction) and CVLT-II 10-minute delayed 
recall (1.33 points reduction). Those with incident anxiety symptoms performed significantly 
worse on only 3MS (3.04 points reduction).  
4.4.4 Anxiety symptoms and clinically significant cognitive decline 
In total, 256 (19%) women had clinically significant cognitive decline in short MMSE over time. 
Compared to women with no anxiety symptoms at baseline, women with mild anxiety symptoms 
were more likely to have cognitive decline (OR = 1.40, 95% CI 1.04, 1.90). However, this 
association did not remain significant after controlling for potential confounding factors 
(multivariable-adjusted OR = 1.24, 95% CI 0.87, 1.76). Moderate/severe anxiety symptoms or 
change in anxiety symptoms over time were not significantly associated with cognitive decline 
(data not shown). 
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4.5 DISCUSSION 
This prospective study showed that mild anxiety symptoms in the oldest old women were 
associated with increased odds of incident dementia over a period of five years, independent of 
multiple confounders including depression. Change in anxiety symptoms over time, as denoted 
by incident and receded anxiety symptoms, was associated with dementia. Our study also 
showed that verbal and working memory were the principal cognitive domains affected by these 
characteristics of anxiety symptoms. To our knowledge, this is the first study to assess the 
relationship between characteristics of anxiety symptoms and subsequent development of 
dementia and MCI in the oldest old community-dwelling women.  
This study is consistent with previous work that showed significant association between 
anxiety and subsequent cognitive impairment.(Burton et al., 2013; Gallacher et al., 2009; Geda et 
al., 2014; Pietrzak et al., 2012; Potvin, Forget, et al., 2011; Sinoff & Werner, 2003) For instance, 
Gallacher et al. (2009) reported that heightened anxiety was associated with clinically assessed 
cognitive impairment in 1,160 older men (aged 48 to 67 years) after 17 years of follow-up. Our 
work extends this finding to oldest old women. Few previous studies examined gender 
differences in the relationship between anxiety and subsequent cognitive impairment. Potvin et 
al. (2011) studied 1,942 older adults and reported that anxiety symptoms, but not disorders, were 
associated with cognitive impairment in women after one year of follow-up. In this same study, 
anxiety disorders, but not symptoms, were associated with cognitive impairment in men. Our 
findings are consistent with this finding in women. However, it is important to note that other 
studies did not find significant association between anxiety and subsequent cognitive 
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impairment.(Bierman et al., 2008; Cherbuin et al., 2009; de Bruijn et al., 2014) Finally, our study 
was in line with one previous study that found a significant quadratic relationship between level 
of anxiety and cognitive function(Bierman et al., 2008). However, our study found that mild 
anxiety symptoms were deleterious for cognitive status, whereas the other study found 
improvement in cognitive function with lower level of anxiety symptoms.  
Three hypotheses have been advanced in the literature attempting to explain the 
relationship between anxiety and cognitive impairment. First, anxiety could be a risk factor for 
cognitive impairment. To support this etiological hypothesis, a dose-response relationship is to 
be expected where increasing level of anxiety symptoms will be associated with increasing level 
of cognitive impairment. Our findings showed that mild but not moderate/severe anxiety 
symptoms were associated with severe but not mild cognitive impairment and as such our study 
does not support this hypothesis. This is based on an assumption that both levels of anxiety 
symptoms and cognitive impairment reflect similar pathological processes across levels, which 
cannot be confirmed or ruled out by our measurements. Persistent anxiety symptoms over time 
were not associated with risk of cognitive impairment, yielding additional support to this 
conclusion. Second, the association between anxiety and cognitive impairment could be 
confounded by shared risk factors, such as depression. However, we controlled for a large 
number of potential confounders and therefore this hypothesis is unlikely to explain our findings.  
Third, anxiety could be a consequence of cognitive impairment. Dementia is a 
degenerative disease with a long prodromal period and thus it is plausible that anxiety may 
appear as an early symptom or as a reaction to subtle cognitive deficits before formal diagnosis 
of a significant cognitive impairment. Thus, our follow-up duration of five years may have been 
too short to rule out this hypothesis. Our findings could be explained by this hypothesis if we 
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viewed mild anxiety symptoms as “prodromal symptoms” of undiagnosed cognitive impairment 
and moderate/severe anxiety symptoms as “true symptoms” of an anxiety disorder. This is 
further supported in our study by the finding that changes, but not persistence, in anxiety 
symptoms over time were associated with dementia. The unstable course in anxiety symptoms, 
denoted by the incident and receded groups, may indicate a gradual change in anxiety symptoms 
over time, which mirrors mild anxiety symptoms or prodromal symptoms. As we did not have 
additional measurements of anxiety between baseline and follow-up, this is a strong assumption 
to make. The association of incident and receded anxiety symptoms (representing two 
contrasting groups) with risk of dementia may reflect the clinical and pathological heterogeneity 
in our sample. While some individuals with cognitive impairment may have poor judgment and 
loss of perception, hindering their anxiety reporting, some may not. 
(AmericanPsychiatricAssociation, 2013) Clinical and pathological heterogeneity may also 
explain our finding of no significant association between anxiety and MCI.  
Strengths of this study include the prospective cohort design, a large, well-characterized 
cohort of community-dwelling oldest old women, clinical adjudication of cognitive impairment 
by an expert panel and consideration of a large number of possible confounders. Our study has 
several limitations. First, our sample was comprised of mostly Caucasian oldest old women, 
which hinders generalizability of findings to younger women, other ethnic groups and men. 
Second, anxiety symptoms were self-reported and were measured by an instrument that was 
developed in young adults. However, GAS has shown moderate validity in a sample of older 
adults.(Pachana et al., 2007) Third, we did not exclude participants with probable cognitive 
impairment based on clinical measures and therefore our sample may have included participants 
with subtle cognitive impairment. We used established criteria to exclude those participants who 
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showed signs of cognitive impairment. Finally, we could not control for residual confounding 
inherent in the observational design of the study. 
Our findings suggest that anxiety symptoms in cognitively healthy oldest old women may 
serve as an important predictor of future risk of dementia. This finding is independent of 
depression, poor sleep, use of psychotropic medications and other important confounders. Future 
studies should explore potential underlying biological mechanisms linking these unique 
characteristics of anxiety symptoms to cognitive impairment in older women. 
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4.6 TABLES AND FIGURES 
Table 4.1 Baseline characteristics of participants according to level of anxiety symptoms at baseline 
Characteristics Total 
N = 1,425 
Anxiety symptoms p-value 
No symptoms 
N = 832 
Mild 
(1-4 symptoms) 
N = 403 
Moderate/severe 
(5-9 symptoms) 
N = 190 
Demographics 
Age, years, mean ± SD 82.8 ± 3.1 82.8 ± 3.0 82.9 ± 3.2 82.6 ± 3.0 0.57 
High school or less, n (%) 863 (60.8) 504 (60.9) 238 (59.2) 121 (63.7) 0.58 
African-American, n (%) 156 (11.0) 84 (10.1) 48 (11.9) 24 (12.6) 0.46 
Married, n (%) 429 (30.1) 201 (24.2) 144 (35.7) 84 (44.2) <0.001 
Medical history 
Stroke, n (%) 144 (10.1) 72 (8.7) 40 (9.9) 32 (16.8) 0.003 
Myocardial infarction, n (%) 148 (10.4) 78 (9.4) 46 (11.4) 24 (12.6) 0.30 
Congestive heart failure, n (%) 94 (6.6) 47 (5.7) 27 (6.7) 20 (10.5) 0.05 
Hypertension, n (%) 853 (59.9) 493 (59.3) 243 (60.3) 117 (61.6) 0.82 
Chronic obstructive pulmonary 
disease, n (%) 
172 (12.1) 85 (10.2) 53 (13.2) 34 (17.9) 0.01 
Diabetes, n (%) 145 (10.2) 85 (10.2) 43 (10.7) 17 (9.0) 0.81 
Osteoarthritis, n (%) 537 (37.7) 272 (32.7) 171 (42.4) 94 (49.5) <0.001 
Rheumatoid arthritis, n (%) 108 (7.6) 59 (7.1) 32 (7.9) 17 (9.0) 0.65 
Breast cancer, n (%) 146 (10.3) 83 (10.0) 37 (9.2) 26 (13.8) 0.21 
Life style 
Take walks for exercise, n (%) 584 (41.4) 347 (42.1) 163 (40.8) 74 (39.6) 0.78 
Number of drinks/week during 
past 30 days, mean ± SD 
1.1 ± 2.8 1.0 ± 2.4 1.3 ± 3.3 1.2 ± 3.0 0.28 
Current caffeine intake (mg/day), 
mean ± SD 
157.3 ± 
154.1 
153.5 ± 154.7 167.2 ± 156.5 153.2 ± 145.6 0.30 
Currently smoke cigarettes, n 
(%) 
20 (1.6) 10 (1.3) 8 (2.3) 2 (1.2) 0.47 
Quality of life 
Self-rated health status, 
good/excellent, n (%) 
1,137 
(79.8) 
703 (84.5) 316 (78.4) 118 (62.1) <0.001 
Any IADL impairment, n (%) 650 (47.8) 332 (41.5) 200 (52.4) 118 (66.3) <0.001 
Pittsburgh Sleep Quality Index > 
5, n (%) 
765 (53.7) 364 (43.8) 230 (57.1) 171 (90.0) <0.001 
Geriatric Depression Scale ≥ 6, n 
(%) 
121 (8.5) 22 (2.6) 42 (10.4) 57 (30.0) <0.001 
Psychotropic medications 
Benzodiazepine use in the past 
30 days, n (%) 
95 (7.0) 40 (5.0) 34 (8.9) 21 (11.7) 0.001 
Non-benzodiazepine non-
barbiturate sedative hypnotic use 
in the past 30 days, n (%) 
13 (1.1) 4 (0.6) 4 (1.2) 5 (3.2) 0.018 
Any antidepressant use in the 
past 30 days, n (%) 
149 (10.9) 69 (8.6) 49 (12.8) 31 (17.2) 0.001 
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SSRI antidepressant use in the 
past 30 days, n (%) 
91 (6.7) 44 (5.5)   31 (8.1) 16 (8.9) 0.11 
TCA antidepressant use in the 
past 30 days, n (%) 
40 (2.9) 19  (2.4) 12  (3.1) 9 (5.0) 0.16 
Table 4.1 Continued
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Table 4.2 Baseline characteristics of participants according to clinical cognitive status at follow-up 
Characteristics Total 
N = 1,425 
Cognitive status p-value 
Normal 
cognition 
N = 857 
Mild cognitive 
impairment 
N = 335 
Dementia 
N = 233 
Anxiety symptoms 0.09 
Mild 403 (28.3) 227 (26.5) 94 (28.1) 82 (35.2) 
Moderate/severe 190 (13.3) 114 (13.3)   43 (12.8) 33 (14.2) 
Demographics 
Age, years, mean ± SD 82.8 ± 3.1 82.5 ± 2.8 82.9 ± 3.3 83.9 ± 3.5 0.001 
High school or less, n (%) 863 (60.8) 480 (56.2) 234 (70.1) 149 (64.2) <0.001 
African-American, n (%) 156 (11.0) 83 (9.7) 45 (13.4) 28 (12.0) 0.15 
Married, n (%) 429 (30.1) 269 (31.4) 91 (27.2) 69 (29.6) 0.35 
Medical history 
Stroke, n (%) 144 (10.1) 76 (8.9) 36 (10.8) 32 (13.7) 0.08 
Myocardial infarction, n (%) 148 (10.4) 78 (9.1) 40 (11.9) 30 (12.9) 0.14 
Congestive heart failure, n (%) 94 (6.6) 58 (6.8) 20 (6.0) 16 (6.9) 0.87 
Hypertension, n (%) 853 (59.9) 516 (60.2) 189 (56.4) 148 (63.5) 0.22 
Chronic obstructive pulmonary 
disease, n (%) 
172 (12.1) 105 (12.3) 42 (12.5) 25 (10.7) 0.78 
Diabetes, n (%) 145 (10.2) 77 (9.0) 37 (11.0) 31 (13.3) 0.13 
Osteoarthritis, n (%) 537 (37.7) 310 (36.2) 131 (39.1) 96 (41.2) 0.31 
Rheumatoid arthritis, n (%) 108 (7.6) 61 (7.1) 29 (8.7) 0.66 
Breast cancer, n (%) 146 (10.3) 87 (10.2) 31 (9.3) 28 (12.0) 0.56 
Life style 
Take walks for exercise, n (%) 584 (41.4) 368 (43.4) 140 (42.0) 76 (33.2) 0.02 
Number of drinks/week during 
past 30 days, mean ± SD 
1.1 ± 2.8 1.2 ± 3.0 1.1 ± 2.8 0.6 ± 1.7 0.001 
Current caffeine intake (mg/day), 
mean ± SD 
157.3 ± 
154.1 
160.8  ± 156.5 158.8  ± 153.5 142.5  ± 145.5 0.28 
Currently smoke cigarettes, n 
(%) 
20 (1.6) 11 (1.4) 7  (2.4) 2 (1.0) 0.43 
Quality of life 
Self-rated health status, 
good/excellent, n (%) 
1,137 
(79.8) 
697 (81.3) 261 (77.9) 179 (76.8) 0.20 
Any IADL impairment, n (%) 650 (47.8) 362 (44.0) 152 (47.7) 136 (62.4) <0.001 
Pittsburgh Sleep Quality Index > 
5, n (%) 
765 (53.7) 472 (55.1) 169 (50.5) 124 (53.2) 0.35 
Geriatric Depression Scale ≥ 6, n 
(%) 
121 (8.5) 53 (6.2) 35 (10.5) 33 (14.2) <0.001 
Psychotropic medications 
Benzodiazepine use in the past 
30 days, n (%) 
95 (7.0) 55 (6.7) 20 (6.2) 20 (9.2) 0.36 
Non-benzodiazepine non-
barbiturate sedative hypnotic use 
in the past 30 days, n (%) 
13 (1.1) 8 (1.1) 1 (0.4) 4 (2.1) 0.22 
Antidepressant use in the past 30 
days, n (%) 
149 (10.9) 65 (7.9) 41 (12.8) 43 (19.7) <0.001 
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Table 4.3 Association between anxiety symptoms and dementia and mild cognitive impairment 
Anxiety 
symptoms 
Dementia** Mild cognitive impairment** 
Unadjusted Multivariable-
adjusted* 
Unadjusted Multivariable-
adjusted* 
Odds ratio (95% confidence interval) 
Model 1 Any 1.47 (1.10, 1.97) 1.56 (1.07, 2.26) 1.05  (0.81, 1.35) 1.07 (0.78, 1.47) 
None 1.00 (reference) 
Model 2 Moderate/severe 1.27 (0.82, 1.96) 1.27 (0.71, 2.28) 0.98 (0.67, 1.45) 0.99 (0.60, 1.62) 
Mild  1.58 (1.14, 2.18) 1.66 (1.12, 2.45) 1.08 (0.81, 1.44) 1.10 (0.79, 1.55) 
None 1.00 (reference) 
Model 3 Incident  1.85 (1.01, 3.39) 1.54 (0.74, 3.20) 2.26 (1.37, 3.73) 1.73 (0.95, 3.15) 
Persistent  1.08 (0.58, 2.03) 0.83 (0.34, 2.03) 0.96 (0.55, 1.67) 0.80 (0.38, 1.70) 
Receded  2.81 (1.17, 6.74) 3.80 (1.22, 11.87) 1.03 (0.37, 2.93) 1.10 (0.31, 3.84) 
Never 1.00 (reference) 
*Models are adjusted for demographics (age, education and marital status), health behaviors (smoking, alcohol use
and exercise), medical history (hypertension, myocardial infarction, stroke, and diabetes), psychotropic medications 
(benzodiazepine, non-benzodiazepine non-barbiturate sedative hypnotic and antidepressant), depression and poor 
sleep. 
**Reference group: normal cognition. 
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Table 4.4 Association between anxiety symptoms and cognitive function tests 
Anxiety  3MS Seconds to 
complete trails B 
CVLT-II, 
immediate recall 
CVLT-II,  
 delayed recall 
Forward Digit 
Span 
Backward Digit 
Span 
Verbal fluency 
test 
Category fluency 
test 
Regression coefficient  
p-value 
Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* 
Any anxiety 
symptom 
-1.19 
0.03 
-1.15 
0.06 
3.95 
0.09 
2.86 
0.28 
-0.88 
<0.01 
-1.05 
<0.01 
-0.35 
0.02 
-0.40 
0.02 
-0.01 
0.96 
0.08 
0.55 
-0.22 
0.05 
-0.23 
0.08 
-0.14 
0.52 
-0.19 
0.45 
-0.37 
0.06 
-0.34 
0.12 
Level 
Mild anxiety -1.23 
0.05 
-1.11 
0.09 
1.94 
0.47 
1.75 
0.54 
-0.86 
0.01 
-1.07 
<0.01 
-0.36 
0.03 
-0.43 
0.02 
-0.02 
0.91 
0.04 
0.79 
-0.27 
0.03 
-0.32 
0.02 
-0.11 
0.67 
-0.20 
0.48 
-0.19 
0.38 
-0.21 
0.38 
Moderate/severe 
anxiety 
-1.10 
0.18 
-1.26 
0.19 
8.22 
0.02 
6.16 
0.14 
-0.93 
0.04 
-1.00 
0.06 
-0.34 
0.12 
-0.31 
0.24 
0.01 
0.94 
0.20 
0.34 
-0.12 
0.48 
0.04 
0.86 
-0.22 
0.52 
-0.18 
0.65 
-0.75 
0.01 
-0.73 
0.03 
Change 
Incident anxiety  -3.12 
0.01 
-3.04 
0.02 
4.68 
0.34 
-1.83 
0.75 
0.04 
0.95 
0.40 
0.57 
-0.08 
0.79 
0.03 
0.93 
-0.30 
0.22 
-0.25 
0.37 
-0.12 
0.61 
-0.07 
0.80 
-0.67 
0.16 
-0.20 
0.71 
-0.58 
0.16 
-0.57 
0.21 
Persistent anxiety -0.23 
0.84 
0.68 
0.63 
9.21 
0.06 
4.59 
0.44 
-0.55 
0.38 
0.01 
0.99 
-0.19 
0.54 
0.05 
0.91 
-0.11 
0.65 
0.19 
0.54 
-0.30 
0.21 
-0.02 
0.95 
-0.55 
0.25 
0.18 
0.76 
-0.86 
0.03 
-0.70 
0.16 
Receded anxiety -3.60 
0.06 
-4.98 
0.03 
13.47 
0.09 
14.20 
0.12 
-1.36 
0.19 
-2.00 
0.10 
-1.08 
0.03 
-1.33 
0.03 
0.20 
0.64 
0.05 
0.91 
0.07 
0.86 
-0.08 
0.86 
-0.71 
0.37 
-1.22 
0.19 
-1.20 
0.08 
-1.11 
0.16 
*Models are adjusted for demographics (age, education and marital status), health behaviors (smoking, alcohol use
and exercise), medical history (hypertension, myocardial infarction, stroke, and diabetes), psychotropic medications 
(benzodiazepine, non-benzodiazepine non-barbiturate sedative hypnotic and antidepressant), depression and poor 
sleep. 
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Group N (%) Baseline ~5 years Follow-up 
Never anxious 410 (64) No symptoms No symptoms 
Incident anxiety 102 (16) No symptoms Moderate/Severe 
symptoms 
Persistent anxiety 100 (16) 
Moderate/severe 
symptoms Moderate/severe 
symptoms 
Receded anxiety 29 (4) 
Moderate/severe 
symptoms No symptoms 
Figure 4.1 Construction of four groups to study changes in anxiety symptoms over time 
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Figure 4.2 Probability of incident dementia by baseline anxiety score 
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5.0  PAPER 3: ANXIETY SYMPTOMS AND RISK OF COGNITIVE DECLINE IN 
OLDER MEN 
5.1 ABSTRACT 
Background: Previous research regarding anxiety as a predictor of future cognitive decline in 
older adults is limited and inconsistent. Depression, a commonly comorbid condition with 
anxiety, has been shown to be a potential risk factor for cognitive decline. We examined the 
independent relationship between anxiety symptoms and subsequent cognitive decline. 
Methods: We included 2,818 community-dwelling older men (mean age = 76.1, SD ±5.3 years) 
who were followed on average for 3.4 years. We assessed anxiety symptoms at baseline using 
the Goldberg Anxiety Scale (GAS; range = 0-9). We assessed cognitive function at baseline and 
at two subsequent visits using the Modified Mini-Mental State examination (3MS; global 
cognition) and the Trails B test (executive function). Clinically significant cognitive decline was 
defined as a reduction of 5 points or more in 3MS score or having worst decile of change in 
Trails B completion time. Participants with probable cognitive impairment (3MS score <80, use 
of dementia medication) at baseline were excluded. Results: At baseline, there were 690 (24%) 
men with mild anxiety symptoms (GAS 1-4) and 226 (8%) men with moderate/severe symptoms 
(GAS 5-9). Men with anxiety symptoms were more likely to have depressed mood, poor sleep, 
more chronic medical conditions and more impairment in activities of daily living compared to 
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those with no anxiety symptoms. Compared to those with no anxiety symptoms at baseline, men 
with any anxiety symptoms were more likely to have clinically significant worsening in Trails B 
completion time (OR = 1.56, 95% CI 1.19, 2.05). The association was attenuated after adjusting 
for potential confounders, including depression and poor sleep, but remained significant (OR = 
1.40, 95% CI 1.04, 1.88). No significant association was observed between anxiety symptoms 
and clinically significant decline in 3MS. Conclusion: In older men, anxiety appears to be a 
potential independent predictor of clinically significant decline in executive function. 
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5.2 INTRODUCTION 
Anxiety and cognitive impairment in older adults are major public health problems. In the United 
States, a nationally representative survey, the National Comorbidity Survey Replication, 
estimated the lifetime prevalence of any anxiety disorder as 16.6% and 9.6% among women and 
men aged 65 years and older, respectively.(Gum et al., 2009) Another nationally representative 
study, the Aging, Demographics and Memory Study, reported the prevalence of dementia as 16% 
and 11% among women and men aged 70 years and older, respectively.(Plassman et al., 2007) 
Both conditions have been related to several adverse health outcomes including increased 
disability and mortality.(WHO, 2012; Wolitzky-Taylor et al., 2010)  
Multiple lines of evidence support a significant association between anxiety and 
cognitive impairment. First, cross-sectional studies documented lower cognitive function in older 
adults with heightened anxiety (Beaudreau & O'Hara, 2009; Bierman et al., 2005; Mantella et al., 
2007; Wetherell et al., 2002), and elevated anxiety symptoms in older adults with cognitive 
impairment.(Andreescu et al., 2014; Geda et al., 2008; Lopez et al., 2003; Lyketsos et al., 2002) 
Second, longitudinal studies have suggested that anxiety increased the risk of progression of mild 
cognitive impairment (MCI) to dementia.(Gallagher et al., 2011; Palmer et al., 2007) Third, a 
number of studies reported that the use of benzodiazepines, a group of anxiolytic medications, 
was associated with risk of cognitive impairment or decline,(Billioti de Gage et al., 2012; 
Gallacher et al., 2012; Lagnaoui et al., 2002; Paterniti et al., 2002) This result potentially 
suggests that benzodiazepine use may be a marker of the underlying condition anxiety, although 
the possibility remains that the medication themselves impair cognition. (Yaffe & Boustani, 
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2014) Finally, there is a high co-occurrence between anxiety and depression(Byers et al., 2010; 
Kessler et al., 2003), which itself is a potential risk factor for cognitive impairment.(Byers & 
Yaffe, 2011; Ganguli, 2009) 
The longitudinal relationship between anxiety and subsequent cognitive impairment in 
older adults remains unclear.(Beaudreau & O'Hara, 2008) Previous longitudinal research 
examining this relationship has reported inconsistent findings, and was limited by small sample 
size, short follow-up, measurement issues and not accounting for important 
confounders.(Bierman et al., 2008; Burton et al., 2013; Cherbuin et al., 2009; de Bruijn et al., 
2014; Gallacher et al., 2009); Okereke and Grodstein (2013); (Pietrzak et al., 2012; Potvin, 
Forget, et al., 2011; Sinoff & Werner, 2003) Previous studies also did not investigate how 
specific characteristics, such as severity, of anxiety are related to cognitive impairment.  
Anxiety disorders have been shown to have unique influence on men compared to 
women, and were associated with lower disability (Baxter et al., 2014) but higher mortality.(van 
Hout et al., 2004) Therefore, it is important to examine the relationship between anxiety and 
cognitive impairment separately for men and women. We are aware of only one prospective 
study that examined this issue in older men (Gallacher et al., 2009), and this study included men 
aged 48 to 67 years and it did not adjust specifically for depression. 
In this longitudinal study, we examined the association between presence and severity of 
generalized anxiety symptoms, and cognitive decline among older men enrolled in the 
Osteoporotic Fractures in Men (MrOS) Study. We hypothesized that anxiety symptoms will be 
associated with increased risk of cognitive decline. 
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5.3 METHODS 
5.3.1 Population 
We utilized data from the Osteoporotic Fractures in Men (MrOS) Study, a prospective cohort 
study of community-dwelling men aged 65 years and older.(Orwoll et al., 2005) In brief, 
5,994 older men were recruited during 2000-2002 from the following 6 locations in the United 
States: Birmingham, Alabama; Minneapolis, Minnesota; Monongahela Valley (near 
Pittsburgh), Pennsylvania; Palo Alto, California; Portland, Oregon; and San Diego, 
California. Men were excluded if they were unable to walk without assistance or had a bilateral 
hip replacement. The institutional review board at each site approved the study and participants 
provided written informed consent.  
For this analysis, we used data collected at 3 visits as follows: baseline (2003-2005; 
MrOS Sleep Visit), visit 2 (2005-2006; MrOS Visit 2) and visit 3 (2007-2009; MrOS Visit 3). 
From the 3,135 participants at baseline, 3,122 men had complete data on measurements of 
anxiety and cognitive function. Of the 3,122 men with complete exposure and outcome data, we 
excluded 162 men with probable cognitive impairment at the baseline, with the 
following criteria: Modified Mini-Mental State examination (3MS) (Teng & Chui, 1987) score 
< 80(Kuller et al., 2003) (n = 106), use of dementia medication (n = 44), or both (n = 12). 
Of the 2,960 cognitively healthy men with complete data, 2,818 men provided data on 
cognitive function at either visit 2 or visit 3, and thus comprised our analytical sample.  
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5.3.2 Measurement of anxiety symptoms 
At the baseline, anxiety symptoms were measured using the Goldberg Anxiety Scale 
(GAS).(Goldberg et al., 1988) GAS is a 9-item self-report instrument that inquires about anxiety 
symptoms experienced in the past month. GAS items span cognitive, affective, and somatic 
symptoms of anxiety, and are rated as yes (1) or no (0) answers with a total score ranging from 0 
to 9. Participants must answer yes to at least 2 of the first 4 items in order to have the subsequent 
5 items included in their total score. The 4 screening items are as follows: being keyed up or on 
edge; worrying a lot; being irritable, and having difficulty relaxing. The recommended cutoff 
score of 5 suggests that a participant has a 50% chance of a clinically significant anxiety, while 
higher scores substantially increase the probability of a significant anxiety disturbance. To study 
the level of anxiety symptoms, we classified participants according to baseline GAS score into 
the following 3 groups: no anxiety (0), mild anxiety (1-4), and moderate/severe anxiety (5-9).  
5.3.3 Measurement of cognitive function 
At the Sleep Visit, Visit 2 and Visit 3, two neuropsychological tests were administered to 
participants: the 3MS and the Trails B.(Reitan & Wolfson, 1985)  
The 3MS assesses global cognitive function with components for orientation, 
concentration, language, praxis, and immediate and delayed memory. The 3MS score ranges 
from 0 to 100 with higher scores indicating better cognitive function. Cognitive decline in the 
3MS is indicated by a negative change, with a lower score at a follow-up measurement. 
Clinically significant cognitive decline in 3MS was defined as a decline of five points or more 
between baseline and visit 3.(Andrew & Rockwood, 2008; Blackwell et al., 2014) 
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The Trails B is primarily a measure of executive function but it also assesses attention, 
sequencing and visual scanning. This is a timed test with 300 seconds allowed to complete it, 
with faster completion time indicating better cognitive function. Cognitive decline in the Trails B 
is indicated by a positive change, with a longer completion time at a follow-up measurement. 
Clinically significant cognitive decline in Trails B was defined as being in the worst decile of 
change between baseline and visit 3 (change of ≥ 65 seconds).(Blackwell et al., 2014; Ganguli et 
al., 1993) 
5.3.4 Other measurements 
At the Sleep Visit, additional measurements were collected via self-report questionnaires. 
Demographic information included age, race, and education. Marital status was obtained at visit 
2. Medical history was defined as prior physician diagnosis of select medical conditions. 
Participants reported smoking status, alcohol use, and self-rated health status. Physical activity 
was assessed using the physical activity scale for the elderly (PASE).(Washburn, Smith, Jette, & 
Janney, 1993) Functional status was assessed by collecting information on difficulty with 5 
instrumental activities of daily living (IADL), which included walking 2 to 3 blocks on level 
ground, climbing up to 10 steps, preparing meals, doing heavy housework, and shopping for 
groceries or clothing. The number of activities that were difficult was summed for a total IADL 
score. The Geriatric Depression Scale (GDS)(Lyness et al., 1997) was used to assess depressive 
symptoms, with the standard cutoff score of 6 or more to define clinically significant depressive 
symptoms. The Pittsburgh Sleep Quality Index (PSQI)(Buysse et al., 1989) was used to assess 
sleep, with the standard cutoff score of 5 or more to define poor sleep. Medication use was 
ascertained by asking participants to bring all current prescription and non-prescription 
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medications used in the past month to their clinic visits. Medications were coded and categorized 
using the Iowa Drug Information Service (IDIS) scheme.(Pahor et al., 1994)  
5.3.5 Statistical analysis 
We calculated descriptive statistics for all variables and compared participants by level of 
anxiety symptoms at baseline. For these comparisons, we used chi-squared test (or Fisher's exact 
test for low expected cell counts) for categorical variables, one-way ANOVA test for normally 
distributed continuous data and the Kruskal Wallis test for skewed continuous data. Next, we 
examined the association of anxiety symptoms with baseline and change in 3MS score and time 
to complete Trails B using repeated measures mixed effects linear regression models. These 
models take into account the within-subject correlation of repeated measures and the missing 
data. The models included random intercept and slope of the cognitive measurements over time, 
assuming an unstructured covariance matrix. Time was modeled as a continuous variable 
indicating years from baseline. Finally, we examined the association of anxiety symptoms with 
clinically significant cognitive decline using logistic regression models. We present unadjusted 
and multivariable-adjusted models. In all models, we adjusted for clinic site, age, depression, 
poor sleep and psychotropic medications (benzodiazepines, non-benzodiazepine non-barbiturate 
sedative hypnotics and antidepressants) due to their potential strong confounding effect on the 
relationship between anxiety and cognitive function. Additional baseline covariates (race, 
education, marital status, medical co-morbidity, physical activity, alcohol, smoking, self-rated 
health and IADL impairment) were selected for inclusion in the multivariable models by  
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manual backward elimination of the least significant variable until all variables were less than 
p=0.05. All statistical analyses were conducted with Stata version 13.1 (StataCorp LP, College 
Station, TX, USA). 
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5.4 RESULTS 
5.4.1 Characteristics of participants 
Baseline characteristics of participants are presented in Table 5.6.1. At baseline, there were 226 
(8%) men who had moderate/severe anxiety symptoms and 690 (24%) who had mild anxiety 
symptoms. Men with moderate/severe or mild anxiety symptoms at baseline were more likely to 
have lower level of education, have depressed mood and poor sleep, take more psychotropic 
medications, suffer from more chronic medical conditions, and have more impairments in daily 
living activities compared to those with no anxiety symptoms. After mean follow-up time of 3.4 
(standard deviation [SD] ±0.5) years, 472 (19%) men had clinically significant decline in global 
cognitive function and 240 (10%) men had clinically significant decline in executive function. 
The mean change in the 3MS score was 1.3 (SD ±5.5) points lower and the mean change in the 
time to complete Trails B was 9.1 (SD ±49.2) seconds longer.  
5.4.2 Anxiety symptoms and 3MS test 
At baseline, there was a statistically significant difference in 3MS score by level of anxiety 
symptoms. Those with no anxiety symptoms at baseline had a mean score of 93.80 points versus 
93.45 and 92.53 for those with mild and moderate/severe symptoms, respectively (p<0.001) 
(Table 5.6.2). The 3-year 3MS score decline was higher among men with mild anxiety symptoms 
compared to those with no symptoms or with moderate/severe symptoms (-1.46 points versus -
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1.08 and -0.84 respectively, p<0.001). Results were similar in the multivariable-adjusted model 
(Figure 5.6.1). There was no significant interaction between anxiety symptoms and time 
(p=0.13).  
The association of anxiety symptoms and clinically significant change in the global 
cognitive outcome is shown in Table 3. Overall, there was no significant association between 
anxiety symptoms, including mild and more severe symptoms, and clinically significant decline 
in 3MS.  
5.4.3 Anxiety symptoms and Trails B test 
At baseline, time to complete Trails B test varied by level of anxiety symptoms. Those with no 
anxiety symptoms at baseline had a mean test completion time of 114.92 seconds versus 119.36 
and 124.42 seconds for those with mild and moderate/severe symptoms, respectively (p=0.01) 
(Table 5.6.2). The 3-year decline in Trails B test (increase in completion time) was more 
prominent in men with moderate/severe anxiety symptoms compared to those with no symptoms 
or with mild symptoms (+15.90 seconds versus +8.27 and +11.80 respectively, p=0.001). In the 
multivariable-adjusted model, similar pattern of change over time was observed but difference 
between groups was marginally significant (p= 0.05). In this model, the anxiety groups were not 
significantly different at baseline (p= 0.42) (Figure 5.6.2). This model showed statistically 
significant interaction term for anxiety symptoms with time (p=0.04), indicating that over time 
those with moderate/severe anxiety had faster decline in executive function.  
There was a consistent association between anxiety symptoms and clinically significant 
worsening of Trails B test completion time (Table 5.6.3). In the multivariable-adjusted model, 
older men with any anxiety symptoms at baseline were 1.40 times more likely to have clinically 
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significant worsening in Trails B test completion time compared to those without any anxiety 
symptoms at baseline (OR = 1.40, 95% CI 1.04, 1.88). This relationship was strongest for 
moderate/severe anxiety symptoms (unadjusted OR = 1.86, 95% CI 1.19, 2.90); however, this 
association was attenuated in the multivariable-adjusted models. 
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5.5 DISCUSSION 
This prospective study showed that older men with anxiety symptoms experienced greater 
declines in both global cognitive function and executive function over 3.4 years compared to 
older men with no anxiety symptoms. The decline reached clinically significant level in 
executive function but not global cognitive function. These findings are independent of 
demographic characteristics, depression, poor sleep and psychotropic medications.  
Our findings are consistent with prospective studies that reported significant associations 
between anxiety and cognitive impairment, but extend these findings to show the cognitive 
domain that may be largely influenced by anxiety in older men is executive function. Prior cross-
sectional studies reported an association between anxiety and poor executive function. 
(Beaudreau & O'Hara, 2009; Bierman et al., 2005; Mantella et al., 2007; Yochim et al., 2013) 
For instance, Mantella et al. found that older adults with generalized anxiety disorder performed 
worse on Trails B compared to healthy controls.(Mantella et al., 2007) Our study replicates these 
findings in a longitudinal design. Our work also is consistent with one prospective study of 1,160 
men aged 48 to 67 years that reported an association between high anxiety level and incident 
cognitive impairment (adjusted OR 2.58, 95% CI 1.11, 5.99).(Gallacher et al., 2009) Our study 
extends this finding to men aged 65 years and older, while adjusting specifically for depression.  
However, it is noteworthy that other prospective studies found significant association 
between anxiety and clinically significant global cognitive function(Potvin, Forget, et al., 2011; 
Sinoff & Werner, 2003), but our study did not. Our study as well was not consistent with other 
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prospective studies that found no association between anxiety and cognitive impairment in older 
adults.(Bierman et al., 2008; Cherbuin et al., 2009; de Bruijn et al., 2014)  
The literature suggests three possibilities to explain the relationship between anxiety and 
cognitive decline. First, anxiety could be a risk factor for cognitive decline. To support this 
etiological hypothesis, a dose-response relationship is to be expected, where increasing level of 
anxiety symptoms will be associated with increasing level of cognitive decline. Our findings 
showed that mild and moderate/severe levels of anxiety had contrasting relationship with 
cognitive function, and as such our study does not support this hypothesis. This is based on an 
assumption that both levels of anxiety symptoms and cognitive domains reflect similar 
pathological processes across levels, which cannot be confirmed or ruled out by our 
measurements. Second, the association between anxiety and cognitive decline could be explained 
by shared risk factors, such as depression. It is noteworthy that about 30% of men with 
moderate/severe anxiety in our study reported clinically significant depressive symptoms. 
However, we adjusted our models for depression and other important potential confounders, and 
therefore this hypothesis is less likely to explain our findings. Third, anxiety could be a 
consequence of cognitive decline. Severe cognitive impairment, such as dementia, is a 
degenerative disease with a long prodromal period, and thus it is plausible that anxiety may 
appear as an early symptom or as a reaction to subtle cognitive deficits before developing 
significant cognitive impairment. Our follow-up duration of 3.4 years may have been too short to 
show a clinically significant decline in global cognitive function. The small but varying influence 
of anxiety symptoms level on global cognitive function and executive functioning may reflect 
clinical and pathological heterogeneity that stirred anxiety symptoms to present differently.  
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Strengths of this study include the prospective cohort design, a large, well-characterized 
cohort of older community-dwelling men, and consideration of a large number of possible 
confounders. Our study has several limitations. First, our sample was comprised of mostly 
Caucasian older men, and our results may not be generalizable to younger men, other ethnic 
groups or women. Second, anxiety symptoms were self-reported without clinical assessment and 
were measured by an instrument that was developed in young adults. However, GAS has shown 
moderate validity in a sample of older adults.(Pachana et al., 2007) Third, our measures of 
cognitive function were limited to measures of global cognitive function and executive function. 
Fourth, we excluded participants with probable cognitive impairment at baseline using 
established criteria for cognitive impairment. However, we did not have clinical assessments and 
therefore our sample may have included participants with subtle cognitive impairment. Finally, 
we could not control for residual confounding inherent in the observational design of the study. 
Our findings suggest that anxiety symptoms in cognitively healthy older men may serve 
as an important predictor of future risk of decline in executive functioning. This finding is 
independent of depression, poor sleep, use of psychotropic medications and other important 
confounders. Future studies should explore potential underlying biological mechanisms linking 
anxiety symptoms to cognitive decline in older men. 
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5.6 TABLES AND FIGURES 
Table 5.1 Characteristics of participants according to level of anxiety symptoms at baseline 
Characteristics Total 
N = 2,818 
Anxiety symptoms, n (%) p-value 
No symptoms 
1,902 (68) 
Mild 
(1-4 symptoms) 
690 (24) 
Moderate/Severe 
(5-9 symptoms) 
226 (8) 
Demographics 
Age, years, mean ± SD 76.1 ± 5.3 76.1 ± 5.3 76.0  ± 5.4 75.8 ± 5.4 0.5 
Non-Caucasian race, n (%) 221 (7.8) 150 (7.9) 51 (7.4) 20 (8.9) 0.8 
High school or less, n (%) 561 (19.9) 357 (18.8) 147 (21.3) 57 (25.2) 0.04 
Married, n (%) 2,286 (81.2) 1,543 (81.3) 566 (82.0) 177 (78.3) 0.5 
Medical history 
Stroke, n (%) 103 (3.7) 61 (3.2) 30 (4.4) 12 (5.3) 0.15 
Parkinson`s disease, n (%) 31 (1.1) 16 (0.8) 8 (1.2) 7 (3.1) 0.01 
Myocardial infarction, n (%) 467 (16.6) 294 (15.5) 121 (17.5) 52 (23.0) 0.01 
Hypertension, n (%) 1,387 (49.2) 883 (46.4) 369 (53.5) 135 (59.7) <0.001 
Chronic obstructive pulmonary 
disease, n (%) 
141 (5.0) 80 (4.2) 40 (5.8) 21 (9.3) <0.01 
Diabetes, n (%) 364 (12.9) 227 (11.9) 100 (14.5) 37 (16.4) 0.06 
Osteoarthritis, n (%) 656 (23.3) 392 (20.6) 175 (25.4) 89 (39.4) <0.001 
Co-morbid conditions, n (%) <0.001 
    0 842 (29.9) 630 (33.1) 169 (24.5) 43 (19.0) 
    1-2 1,733 (61.5) 1,137 (59.8) 452 (65.5) 144 (63.7) 
    3+ 243 (8.6) 135 (7.1) 69 (10.0) 39 (17.3) 
Life style 
Physical Activity Scale for the 
Elderly score, mean ± SD 
148.6 ± 71.3 148.4 ± 70.1 153.7 ± 74.2 134.7 ± 70.4 <0.01 
Alcoholic drinks per week, 
mean ± SD 
2.9  ± 1.3 2.9  ± 1.2 3.0  ± 1.3 2.7 ± 1.3 0.02 
Smoking status 0.4 
    Never, n (%) 1,124 (39.9) 772 (40.6) 270 (39.1) 82 (36.3) 
    Past, n (%) 1,636 (58.0) 1,092 (57.4) 408 (59.1) 136 (60.2) 
    Current, n (%) 58 (2.1) 38 (2.0) 12 (1.8) 8 (3.5) 
Quality of life 
Self-rated health status, 
good/excellent, n (%) 
2,466 (87.5) 1,732 (91.1) 598 (86.7) 136 (60.2) <0.001 
Any IADL impairment, n (%) 544 (19.3) 310 (16.3) 145 (21.0) 89 (39.4) <0.001 
Pittsburgh Sleep Quality Index 
> 5, n (%) 
1,208 (42.9) 653 (34.3) 366 (53.0) 189 (83.6) <0.001 
Geriatric Depression Scale 
≥ 6, n (%) 
155 (5.5) 29 (1.5) 59 (8.6) 67 (29.8) <0.001 
Psychotropic medications 
Benzodiazepine use, n (%) 117 (4.2) 57 (3.0) 30 (4.4) 30 (13.3) <0.001 
Non-benzodiazepine non-
barbiturate sedative hypnotic 
use, n (%) 
60 (2.1) 31 (1.6)   17 (2.5) 12 (5.3) <0.01 
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Any antidepressant use, n (%) 192 (6.8) 96 (5.1)   52 (7.6) 44 (19.5) <0.001 
SSRI antidepressant use n (%) 102 (3.6) 52 (2.7) 27 (3.9) 23 (10.2) <0.001 
TCA antidepressant use, n (%) 37 (1.3) 20 (1.1)   9 (1.3) 8 (3.5) 0.01 
Table 5.1 Continued
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Table 5.2 Unadjusted mean baseline and 3-year change in cognitive function by anxiety symptoms at baseline 
 Anxiety symptoms Baseline 3MS 
score 
3MS score 3-
year change 
Baseline time to 
complete Trails 
B 
Time to 
complete Trails 
B 3-year change 
Model 1 Any  93.23 -1.31 120.61 +12.81 
 None 93.80 -1.08 114.92 +8.27 
 p-value 0.001 0.001 0.01 0.001 
Model 2 Moderate/severe  92.53 -0.84 124.42 +15.90 
 Mild  93.45 -1.46 119.36 +11.80 
 None 93.80 -1.08 114.92 +8.27 
 p-value <0.001 <0.001 0.01 0.001 
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Table 5.3 Association between anxiety symptoms and clinically significant cognitive decline 
 Anxiety 
symptoms 
3MS score decline of five points or 
more 
Trails B worst decile of change 
Unadjusted Multivariable-
adjusted* 
Unadjusted Multivariable-
adjusted** 
Odds ratio (95% confidence interval) 
Model 1 Any  1.12 
(0.91, 1.39) 
1.07 
(0.85, 1.35) 
1.56 
(1.19, 2.05) 
1.40 
(1.04, 1.88) 
 None 
 
1.00 (reference) 
 
Model 2 Moderate/severe 0.99 
(0.67, 1.46) 
0.80 
(0.51, 1.25) 
1.86 
(1.19, 2.90) 
1.35 
(0.81, 2.27) 
 Mild  1.17 
(0.93, 1.47) 
1.14 
(0.89, 1.46) 
1.47 
(1.09, 1.99) 
1.41 
(1.03, 1.93) 
 None  1.00 (reference) 
*Models are adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race, education, marital 
status and IADL impairments. 
**Models are adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race and IADL 
impairments. 
 
 100 
 
 
*Model is adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race, education, marital 
status and IADL impairments. [baseline p= <0.01, change p= <0.01] 
 
Figure 5.1 Multivariable-adjusted 3MS score by anxiety groups 
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*Model is adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race, education, marital 
status and IADL impairments. [baseline p= 0.42, change p= 0.05] 
 
Figure 5.2 Multivariable-adjusted Trails B time by anxiety group 
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6.0  DISCUSSION   
6.1 SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
The primary aim of this dissertation was to investigate anxiety symptoms in older adults with a 
focus on medications that are used to manage anxiety and impact of anxiety on future cognitive 
functioning. The aim of the first paper was to investigate the trend of anxiolytic and 
antidepressant medications use in older community-dwelling men and women, and to explore 
gender-specific predictors of use of these medications over time.  We found that the use of 
anxiolytic and antidepressant medications increased in this aging cohort over ten years with 
higher prevalence in women than men. We also found that some predictors of anxiolytic and 
antidepressant medications use were common among men and women, while some predictors 
were potentially gender-specific. To our knowledge, this is the first longitudinal study that 
explored gender-specific predictors of anxiolytic and antidepressant medications use in older 
adults in the United States. The aim of the second paper was to investigate the relationship 
between presence, level and changes in anxiety symptoms, and risk of future dementia, MCI and 
decline in cognitive functioning among the oldest old community-dwelling women. We found 
that mild anxiety symptoms in oldest old women were associated with increased odds of incident 
dementia over five years. We also found that change in anxiety symptoms over time, as denoted 
by incident and receded anxiety symptoms, was associated with increased risk of dementia. We 
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did not observe an association between anxiety symptoms and MCI. To our knowledge, this is 
the first longitudinal study that explored the relationship between anxiety symptoms and 
cognitive impairment in the oldest old women in the United States. The aim of the third paper 
was to investigate the relationship between presence and level of anxiety symptoms, and risk of 
future cognitive decline among older community-dwelling men. We found that anxiety 
symptoms in older men were associated with greater declines in both global cognitive function 
and executive function over three years. We also found that such a decline reached clinically 
significant level in executive function but not global cognitive function. To our knowledge, this 
is the first longitudinal study that explored the relationship between anxiety symptoms and 
cognitive decline in older men in the United States.  
Taken together, these findings highlight the importance of anxiety symptoms in older 
adults. Our finding that anxiolytic and antidepressant medications use in older adults was 
increasing may indicate either new reporting of previously undertreated condition or 
inappropriate use of these medications. Both possibilities are alarming given the greater 
morbidity and mortality associated with a condition such as anxiety and the increased 
vulnerability of older adults to psychotropic medications. Our finding that mild but not 
moderate/severe anxiety symptoms were associated with dementia but not with MCI may reflect 
unique pathological profiles, which presented by varying level of anxiety symptoms. Similarly, 
our finding that anxiety symptoms were associated with clinically significant decline in 
executive functioning but not in global cognitive functioning may also point toward clinical and 
pathological heterogeneity. This is critical for better understanding of the nature of the 
relationship between anxiety and cognitive impairment. Our findings regarding anxiety 
symptoms and subsequent cognitive impairment suggest that anxiety is likely an early symptom 
 104 
or a reaction to subtle cognitive deficits before the occurrence of significant cognitive 
impairment. However, these findings do not completely rule out the possibility that anxiety may 
be a potential risk factor for cognitive impairment as they may be specific to our samples. 
Finally, our findings from the three papers extend the literature specific to older men and women 
and emphasize the importance of considering men and women separately when studying late-life 
anxiety. 
Thus, future studies should explore the determinants of anxiety symptoms in older men 
and women, especially the oldest old. Additionally, future studies should investigate 
determinants of prescribing of anxiolytic medications by healthcare providers and whether this 
varies by gender of the older patient. Future research should also explore potential underlying 
biological pathways that may link anxiety symptoms to cognitive impairment that are specific to 
older men or women. Due to heterogeneity of anxiety and cognitive impairment, future studies 
should examine how specific characteristics of anxiety, such as level, changes and type, are 
related to different domains and levels of cognitive impairment. Finally, changes over time of 
potential confounders of the relationship between anxiety and cognitive impairment, such as 
depression and psychotropic medications, should be taken into account in future studies. 
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6.2 PUBLIC HEALTH IMPLICATIONS 
Worldwide, anxiety disorders are the sixth leading cause of all years of life lived with disability, 
ahead of diabetes, cancers and stroke. (Baxter et al., 2014) In the United States, anxiety disorders 
are the most common mental disorders among older adults, with a lifetime prevalence of 16.6% 
among women and 9.6% among men aged 65 years and older. (Gum et al., 2009) Symptoms and 
disorders of anxiety in older adults have been associated with increased risk of disability and 
mortality. (Wolitzky-Taylor et al., 2010)  Further, it is well documented that anxiety in older 
adults is co-morbid with psychiatric conditions, including depression, medical conditions, 
including cardiovascular disease, and cognitive impairment, including Alzheimer's 
disease.(Wolitzky-Taylor et al., 2010) Therefore, management of anxiety symptoms and 
disorders in older adults will have significant implications for public health. In addition to 
reducing suffering experienced by patients with anxiety, treating anxiety has the potential to 
prevent developing other burdensome conditions, such as cognitive impairment, and reduce 
disability and mortality. Thus, findings from this research will help in understanding the role of 
anxiety as a predictor of future cognitive impairment and whether anxiety can early identify 
those at higher risk or it is a potentially modifiable risk factor. While pharmacotherapy is 
effective in managing anxiety disorders, it bears its risks in older adults. Thus, findings from this 
research will inform future intervention research that target older users of anxiety-related 
medications. 
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APPENDIX A 
TABLE OF LONGITUDINAL STUDIES 
Table 6.1 Longitudinal studies that investigated the association between generalized anxiety and cognitive 
impairment in older adults 
Author 
(year) 
Country Sample  Follow-up, 
years 
Exposure 
measure 
Outcome 
measure 
Adjusted 
covariates 
Main findings 
Sinoff 
and 
Werner 
(2003)  
Israel 137 older 
adults, 78.9 
years mean 
age, 27% 
lost to 
follow-up 
3.1 (mean) Anxiety 
symptoms 
(Sinoff’s Short 
Anxiety 
Screening Test, 
score ≥24) 
Cognitive 
impairment 
(Mini-Mental 
State 
Examination, 
score <24) 
Age, gender, 
education, 
marital status, 
depression, loss 
of memory 
complaint 
Those suffering 
of anxiety had 
higher risk for 
developing 
cognitive 
impairment 
(adjusted relative 
risk = 3.96, 95% 
confidence 
interval 1.69, 
9.08) 
Bierma
n et al. 
(2008) 
Netherl
ands 
2,351 older 
adults, 69.5 
years mean 
age, 53.5% 
female, 
37.5% lost 
to follow-
up 
9 Anxiety 
symptoms 
(Hospital 
Anxiety and 
Depression 
Scale) 
Cognitive decline 
(Mini-Mental 
State 
Examination, 
Raven's Colored 
Progressive 
Matrices, Rey 
Auditory Verbal 
Learning Test 
Age, gender, 
education, 
alcohol, 
benzodiazepine, 
number of 
chronic diseases, 
depression 
Previous 
measurement of 
anxiety 
symptoms was 
not associated 
with cognitive 
decline at a later 
time point 
Cherbui
n et al. 
(2009) 
Australi
a 
2,083 older 
adults, 62.4 
years mean 
age, 13% 
lost to 
follow-up 
4 Anxiety 
symptoms 
(Goldberg 
Anxiety Scale) 
Mild cognitive 
impairment, mild 
cognitive 
disorder (clinical 
diagnosis) 
Age, gender, 
education, body 
mass index, 
blood pressure, 
forced vital 
capacity, visual 
acuity, arthritis, 
Anxiety 
symptoms were 
not associated 
with mild 
cognitive 
impairment or 
mild cognitive 
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diabetes, physical 
health self-report, 
mental health 
self-report, 
depression, 
smoking, alcohol, 
APOE, 
medications 
(blood pressure, 
cholesterol, 
anxiety, 
depression)  
disorder. Taking 
anxiety 
medications was 
only associated 
with mild 
cognitive 
impairment in a 
model adjusted 
for age, gender 
and education 
(odds ratio = 
4.08, 95% 
confidence 
interval 1.16, 
14.39) 
Gallach
er et al. 
(2009) 
United 
Kingdo
m 
1,160 older 
men, 56.1 
years mean 
age, 20% 
lost to 
follow-up 
17.3 (mean) Anxiety 
symptoms (State 
Trait Anxiety 
Inventory, 31st-
95th centile) 
Dementia, 
cognitive 
impairment not 
dementia, 
(clinical 
adjudication, 
DSM-IV criteria) 
Age, social class, 
marital status, 
smoking, alcohol, 
blood pressure, 
body mass index, 
cholesterol, 
previous vascular 
disease, 
psychological 
distress, 
premorbid 
cognitive 
function 
High anxiety 
level was 
associated with 
any cognitive 
impairment 
(adjusted odds 
ratio 2.58, 95% 
confidence 
interval 1.11, 
5.99) and with 
cognitive 
impairment not 
dementia 
(adjusted odds 
ratio = 2.98, 95% 
confidence 
interval 1.20, 
7.38) 
Potvin, 
Forget, 
et al. 
(2011) 
Canada 1,942 older 
adults, 74.3 
years mean 
age, 20.5% 
lost to 
follow-up 
1 Anxiety 
disorders, 
symptoms 
(clinical 
diagnosis, DSM-
IV criteria) 
Cognitive 
Impairment 
(Mini-Mental 
State 
Examination, 
score <15th 
percentile) 
Age, education, 
gender, living 
area, cognitive 
score at baseline, 
psychotropic 
drugs, brain 
disorders, 
cardiovascular 
conditions, 
number of 
chronic diseases, 
depression 
In men, anxiety 
disorders but not 
symptoms were 
associated with 
cognitive 
impairment 
(adjusted odds 
ratio = 6.27, 95% 
confidence 
interval 1.39, 
28.29). In 
women, anxiety 
symptoms but 
not disorders 
were associated 
with cognitive 
impairment 
(adjusted odds 
ratio = 2.14, 95% 
confidence 
interval 1.06, 
4.34) 
Pietrzak Australi 263 older 2 Pathologic worry Cognitive decline Age, depression Mildly elevated 
Table 6.1 Continued
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et al. 
(2012) 
a adults, 61.6 
years mean 
age, 71.1% 
female, 
25.9% lost 
to follow-
up 
(Penn State 
Worry 
Questionnaire, 
median split into 
mildly elevated 
worry and 
minimal worry 
groups) 
(CogState 6-task 
test battery) 
worry was 
associated with 
decline in a test 
of visual learning 
and memory 
(adjusted odds 
ratio = 3.83, 95% 
confidence 
interval 1.03, 
14.28) 
Burton 
et al. 
(2013) 
United 
Kingdo
m 
400 
dementia 
cases 
(81.40 
years mean 
age, 62% 
female), 
1353 
controls 
(80.87 
years mean 
age, 63% 
female) 
Case-
control 
study 
period: 
2000-2008 
Anxiety 
diagnosis 
(primary care 
records) 
Dementia 
diagnosis 
(primary care 
records) 
Age, gender, 
practice, year of 
case diagnosis of 
dementia, 
hypertension, 
ischemic heart 
disease, 
cerebrovascular 
disease, 
hypotension, 
dyslipidaemia, 
diabetes, 
depression 
Past anxiety 
diagnosis was 
associated with a 
future dementia 
diagnosis 
(adjusted odds 
ratio = 2.67, 95% 
confidence 
interval 2.01, 
3.54). Having 
anxiety diagnosis 
alone was 
associated with 
dementia 
diagnosis in men 
(adjusted odds 
ratio = 3.12, 95% 
confidence 
interval 1.78, 
5.47) but not in 
women 
Okereke 
and 
Grodste
in 
(2013) 
United 
States 
16,351 
older 
women, 63 
years mean 
age 
4.4 years 
(mean) 
Phobic anxiety 
symptoms 
(Crowne-Crisp 
Index; 0-1, 2, 3, 
4, 5 and 6-16) 
Cognitive decline 
(Telephone 
Interview for 
Cognitive Status 
[TICS], East 
Boston Memory 
Test, category 
fluency test, 
TICS delayed 10-
word recall, digit 
span backward) 
Age, education 
level, cigarette 
smoking, current 
postmenopausal 
hormone use, 
hypertension, 
diabetes, elevated 
cholesterol, heart 
disease, body 
mass index, 
alcohol intake, 
physical activity 
level and 
depression 
There were no 
relations between 
phobic anxiety 
and subsequent 
cognitive change 
de 
Bruijn 
et al. 
(2014) 
Netherl
ands 
Sample 1: 
2,708 older 
adults, 68.6 
years mean 
age, 55% 
female 
Sample 2: 
3,069 older 
adults, 75.5 
Sample 1: 
11.8 (mean) 
Sample 2: 
5.8 (mean) 
Sample 1: 
anxiety 
symptoms 
(Hospital 
Anxiety and 
Depression 
Scale, score ≥ 8) 
Sample 2: 
anxiety disorders 
Dementia 
(clinical 
adjudication, 
DSM-III-R 
criteria), 
cognitive decline 
(Letter-Digit 
Substitution 
Task, Stroop 
Test, Verbal 
Fluency Test, 
Age, gender, 
education, 
APOE, 
depression 
No association 
between anxiety 
symptoms or 
disorders with 
risk of dementia 
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years mean 
age, 59% 
female 
(Composite 
International 
Diagnostic 
Interview) 
Verbal Learning 
Test) 
Geda et 
al. 
(2014) 
United 
States 
1,587 older 
adults, 79.3 
years 
median age, 
50% female 
5 (median) Anxiety 
symptom 
(Neuropsychiatri
c Inventory 
Questionnaire) 
Mild cognitive 
impairment 
(clinical 
adjudication, 
Mayo Clinic 
criteria) 
Age, gender, 
education, 
medical 
comorbidity 
Anxiety 
significantly 
predicted 
incident mild 
cognitive 
impairment 
(hazard ratio = 
1.87, 95% 
confidence 
interval1.28, 
2.73) 
Zilkens 
et al. 
(2014) 
Australi
a 
13, 568 
dementia 
cases aged 
65 to 84 
years were 
sex- and 
age-
matched to 
a control 
Case-
control 
study 
period: 
1966-2009 
Anxiety disorder 
diagnosis 
(administrative 
health records) 
Dementia 
diagnosis 
(administrative 
health records) 
Diabetes, heart 
disease, 
cerebrovascular 
disease and 
smoking 
Past anxiety 
disorder 
diagnosis was 
associated with 
future dementia 
diagnosis 
(adjusted odds 
ratio = 1.37, 95% 
confidence 
interval 1.14, 
1.65) 
Pietrzak 
et al. 
(2015); 
Pietrzak 
et al. 
(2014) 
Australi
a 
333 older 
adults, 70 
years mean 
age, 50% 
with 
subjective 
memory 
complaints 
and 50% 
APOE ε4 
carriers 
4.5 Hospital Anxiety 
and Depression 
Scale, elevated 
symptoms (> 
median score of 
4), clinically 
meaningful 
anxiety (score ≥ 
8) 
Cognitive 
function: verbal 
memory 
composite score, 
visual memory 
composite score, 
executive 
function 
composite score, 
language 
composite score, 
attention 
composite score, 
visuospatial 
composite score 
and global 
cognition score. 
Age, educational 
level, IQ, APOE 
genotype, 
subjective 
memory 
complaints, 
number of 
vascular risk 
factors, 
depression 
Baseline elevated 
anxiety 
symptoms were 
associated with 
lower overall 
global cognition 
score, and greater 
decline in global 
cognition and 
verbal memory 
over time. 
Table 6.1 Continued
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APPENDIX B 
GOLDBERG ANXIETY SCALE ITEMS RESPONSES 
Table 6.2 Positive responses to items in the Goldberg Anxiety Scale in SOF and MrOS 
Goldberg Anxiety Scale items, “Yes” response, n (%) SOF sample 
N = 1,425 
MrOS sample 
N = 2,818 
Have you felt keyed up or on edge? 365 (25.61) 501 (17.78) 
Have you been worrying a lot? 315 (22.11) 360 (12.78) 
Have you been irritable? 188 (13.19) 471 (16.71) 
Have you had difficulty relaxing? 250 (17.54) 306 (10.86) 
Have you been sleeping poorly? 486 (34.13) 659 (23.39) 
Have you had headaches or neck aches? 399 (28.00) 550 (19.52) 
Have you had any of the following: trembling, tingling, dizzy 
spells, sweating, frequency, diarrhea? 
540 (37.89) 782 (27.76) 
Have you been worried about your health? 299 (20.98) 458 (16.25) 
Have you had difficulty falling asleep? 448 (31.46) 462 (16.39) 
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APPENDIX C 
FACTOR ANALYSIS FOR PAPER 2 
Table 6.3 Profiles of anxiety symptoms in the SOF sample 
Goldberg Anxiety Scale items *Factor 1 
“Worry profile” 
31% variance 
*Factor 2 
“Sleep profile” 
23% variance 
*Factor 3 
“Somatic profile” 
17% variance 
Have you felt keyed up or on edge? X   
Have you been worrying a lot? X   
Have you been irritable? X   
Have you had difficulty relaxing? X X  
Have you been sleeping poorly?  X  
Have you had headaches or neck aches?   X 
Have you had any of the following: trembling, 
tingling, dizzy spells, sweating, frequency, 
diarrhea? 
  X 
Have you been worried about your health? X  X 
Have you had difficulty falling asleep?  X  
*Based factor loadings > 0.30 with Varimax rotation and using a polychoric correlation matrix. 
 
 
Table 6.4 Association between profiles of anxiety symptoms and dementia and mild cognitive impairment 
Profiles of anxiety 
symptoms 
Dementia** Mild cognitive impairment** 
Unadjusted Multivariable-
adjusted* 
Unadjusted Multivariable-
adjusted* 
Odds ratio (95% confidence interval) 
Worry 1.64 (1.10, 2.45) 1.50 (0.89, 2.53) 1.17 (0.82, 1.68) 1.24 (0.79, 1.94) 
Sleep 0.81 (0.58, 1.13) 0.76 (0.47, 1.23) 0.89 (0.66, 1.18) 0.90 (0.61, 1.34) 
Somatic  1.12 (0.80, 1.56) 0.84 (0.55, 1.28) 1.10 (0.83, 1.47) 0.86 (0.61, 1.22) 
*Models are adjusted for demographics (age, education and marital status), health behaviors (smoking, alcohol use 
and exercise), medical history (hypertension, myocardial infarction, stroke, and diabetes), psychotropic medications 
(benzodiazepine, non-benzodiazepine non-barbiturate sedative hypnotic and antidepressant), depression and poor 
sleep. 
**Reference group: normal cognition. 
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APPENDIX D 
FACTOR ANALYSIS FOR PAPER 3 
Table 6.5 Profiles of anxiety symptoms in the MrOS sample 
Goldberg Anxiety Scale items *Factor 1 
“Worry profile” 
31% variance 
*Factor 2 
“Sleep profile” 
22% variance 
*Factor 3 
“Somatic profile” 
18% variance 
Have you felt keyed up or on edge? X   
Have you been worrying a lot? X   
Have you been irritable? X   
Have you had difficulty relaxing? X X  
Have you been sleeping poorly?  X  
Have you had headaches or neck aches?   X 
Have you had any of the following: trembling, 
tingling, dizzy spells, sweating, frequency, 
diarrhea? 
  X 
Have you been worried about your health? X  X 
Have you had difficulty falling asleep?  X  
*Based factor loadings > 0.30 with Varimax rotation and using a polychoric correlation matrix. 
 
 
Table 6.6 Association between profiles of anxiety symptoms and cognitive decline 
Profiles of anxiety 
symptoms 
3MS score decline of five points or 
more 
Trails B worst decile of change 
Unadjusted Multivariable-
adjusted* 
Unadjusted Multivariable-
adjusted** 
Odds ratio (95% confidence interval) 
Worry 1.05 (0.76, 1.44) 0.98 (0.68, 1.41) 1.79 (1.22, 2.63) 1.58 (1.02, 2.45) 
Sleep 1.25 (0.96, 1.63) 1.22 (0.88, 1.69) 1.35 (0.96, 1.90) 1.11 (0.74, 1.68) 
Somatic  1.51 (1.19, 1.92) 1.32 (1.01, 1.73) 1.86 (1.37, 2.54) 1.58 (1.12, 2.22) 
*Model is adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race, education, marital 
status and IADL impairments. 
**Model is adjusted for clinic site, age, depression, poor sleep, psychotropic medications, race and IADL 
impairments. 
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